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Cannabinoid CB2 receptors modulate ERK-1/2 kinase





Due to diverse physiological effects of cannabinoids, the endocannabinoid system has attracted
major attention as a potential therapeutic target for a broad range of diseases. In the nervous system,
neurotransmission and neuroinflammation are mediated by the endocannabinoid signalling system
(Fernández-Ruiz, 2009; Marrset al., 2010). To date, two cannabinoid (CB) receptors have been
identified by molecular cloning, namely, CB1 and CB2. CB1 receptors are expressed by the neurones
and regulate the release of neurotransmitters, while CB2 receptors are expressed by the microglia,
regulating their motility and immunomodulator production (Howlett et al., 2002; Pertwee et al.,
2010; receptor nomenclature follows Alexander et al., 2011). Endogenous ligands for the
cannabinoid receptors were discovered soon after their characterization. The two major known
endogenous ligands are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Both are
arachidonic acid derivatives produced from phospholipid precursors through activity-dependent
activation of specific phospholipase enzymes (Massi et al., 2013). 2-AG is high efficacy agonist at
CB2, while AEA has a low efficacy at CB2, often functioning as a weak partial agonist (Atwood et
al., 2010).
Both CB1 and CB2 receptors are Gi/o-protein-coupled and are able to signal through the three main
components of the MAPK pathway, namely, ERK, JNK and p38 (Howlett et al., 2002). However,
activation of CB receptors is heavily influenced by cell type specificity, and their signalling is
remarkably complex (Figure 1) (Bosier et al., 2010); indeed, they are able to exploit a wide variety
of pathways to regulate the activities of MAPKs. In fact, CB receptor coupling to MAPKs is
extremely dependent on the cellular context and a wide range of activation and inhibition has been
observed dependent on cell type, cell differentiation status and co-modulators of MAPK cascades
(Howlett, 2005). 
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Figure 1: Cannabinoid receptors signalling. Bosier et al., Biochem Pharmacol 80 (2010) 1-12.
In the nervous system, activation of CB1 and CB2 receptors is induced by the endocannabinoids,
AEA and 2-AG, produced by the neurons and glia (Massi et al, 2013). However, ample evidence
suggests that additional receptors may contribute to the behavioral, vascular and immunological
actions of Δ9-tetrahydrocannabinol (THC), the major psychoactive constituent of marijuana, and
endocannabinoids (Begg et al., 2005). In particular, it has been established that GPR55 is an
additional novel cannabinoid receptor (Lauckner et al., 2008; Bondarenko 2014).
During CNS inflammation, both CB1 and CB2 receptors mediate the induction of MAPK
phosphatase-1 (MKP-1) by the endocannabinoid AEA. Rapid AEA-induced MKP-1 expression
switches off MAPK signal transduction in microglial cells and thereby protects neurons from
inflammatory damage (Eljaschewitsch et al., 2006). Furthermore, it has recently been reported that
both the pharmacological stimulation of CB2 receptors and the manipulation of endocannabinoid
tone by inhibiting AEA hydrolysis in microglia, could modify the cytokine milieu, thereby
contributing to the accumulation of anti-inflammatory microglia at lesion sites in multiple sclerosis
(Correa et al., 2010; 2011). Moreover, another recent study has demonstrated that administration of
2-AG ameliorates both acute and chronic experimental autoimmune encephalomyelitis, a widely
used model of multiple sclerosis (Lourbopoulos et al., 2011).
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Microglia
Microglia, which may constitute as many as 12% of the cells in the central nervous system (CNS),
were described by del Rio-Hortega as a distinct cell type within the CNS with characteristic
morphology and specialized staining characteristics that differentiated them from other glial cells
and neurons. In recent years the advent of monoclonal antibodies to define cell surface determinants
has led to the identification of microglia as a specialized macrophage population in the CNS,
quiescent in the normal brain. However, after CNS injury or upon LPS interaction with Toll-like
receptor (TLR)-4 during bacterial infection (González-Scarano and Baltuch, 1999), these cells can
be activated by cytokines, produced by infiltrating immune effector cells. Thus, LPS stimulation of
the microglia is a useful model for the study of mechanisms underlying neuronal injury by various
pro-inflammatory and neurotoxic factors released by activated microglia (Jung et al., 2010).
Microglial activation results in changes in morphology (e.g., complement receptors, scavenger
receptors), and changes in function (Figure 2) (e.g., migration to sites of damage phagocytosis and
the release of oxygen radicals, proteases, pro-inflammatory cytokines and NO) (Fricker et al., 2012;
Grace et al., 2014). Cumulative evidence shows that, while the NO free radical may play an
important role in host defence against certain intracellular pathogens, it may also contribute to
neuropathology (Hanisch and Kettenmann, 2007). Hence, agents that suppress microglial cell
activation may be beneficial in the treatment of neurodegenerative diseases.
Figure 2: Signalling to microglia. Under inflammatory condition, a variety of constitutively
expressed and inducible receptors may promote migration as well as induce or downregulate
immune effector functions of microglia. Aloisi, Glia 36 (2001) 165-179.
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Cannabinoid CB2 receptors
Cannabinoid CB2 receptor is a G protein-couple receptor expressed mainly in microglia and
peripheral immune cells, modulating antigen presentation, cytokine/chemokine production, and cell
migration. The expression of CB2 receptor was increased in brain injury and many types of
neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis,
Huntington’s chorea (Lei Ma et al., 2015). CB2 is an attractive therapeutic target; activation of CB2
receptors has anti-inflammatory effects (Klein and Newton, 2007; Romero-Sandoval et al., 2009;
Correa et al., 2010; Hsieh et al., 2011). In particular, activation of CB2 receptors expressed in brain
microglia during neuroinflammation (Benito et al., 2008; Atwood and Mackie, 2010) reduced NO
production and TNF-α in primary microglia (Ehrhart et al., 2005). Furthermore, it protected against
human microglial neurotoxicity by enhancing IL-10 production (Klegeris et al., 2003; Correa et al.,
2005; 2010; Eljaschewitsch et al., 2006).
However, the specific intracellular mechanism of action by which CB2 receptor activation alters the
microglial phenotype still remains to be elucidated. Hence, building on previous studies of the role
of CB2 receptors in microglial cells, the rationale behind this study was to confirm and further
explore the role of this receptor subtype in immune modulation within the CNS. In particular, we
set out to characterize CB2 receptor cell signalling, to verify whether the CB2 receptor is coupled to
the activation of MAPKs and to determine its role in NO production. In this way, we aimed to
provide a comprehensive description of the signal transduction mechanisms coupled to CB2
receptor activation.
To this end, we examined the effect of stimulating CB2 receptors in quiescent and LPS-activated
murine microglial cell line N9 and primary murine microglia. We found that CB2 receptors exerted
different effects on ERK activation in microglial cells, depending on the duration of cannabinoid
challenge and the state of cell activation. We observed reversal of ERK phosphorylation in the LPS-
treated microglial cells following 30 min of CB2 receptor activation, a negative feed-back loop
dependent on NO. This phenomenon was shown to diminish the response of microglial cells to
LPS, by reducing NO synthesis and thereby regulating neuroinflammation. Hence, our findings





Tissue culture media and growth supplements were acquired from Cambrex (Bergamo, Italy).
U0126 (MEK-1 and MEK-2 inhibitor, soluble in DMSO), human anti-ACTIVE®MAPK
(phosphorylated Thr183/Tyr185) and human anti-ERK 1/2 pAb were purchased from Promega (Milan,
Italy). Phosphorylated (Thr 180/Tyr182) and total p38, phosphorylated (Thr183/Tyr185) and total JNK-
1/2, anti-iNOS and phosphorylated Ser 338 Raf antibodies were from Cell Signaling Technology
(Celbio, Milan, Italy). JWH-015 (1-propyl-2-methyl-3-(1-naphthoyl)indole) (soluble in ethanol) and
anti-CB2 receptor rabbit polyclonal antibody (ALX-210–198) were provided by Enzo Life Sciences
(Vinci-Biochem, Vinci, Florence, Italy).
The immunogen for the CB2 receptor antibody was a synthetic peptide corresponding to residues
20–33 of the human CB2 receptor N-terminal. Anti-TLR4 (sc-30002), small interfering RNA
(siRNA) for TLR4 (sc-40261) and siRNA for the CB2 receptor (sc-39913) were from Santa Cruz
Biotechnology (DBA, Milan, Italy). AM 251, N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4
iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide and AM 630 (AM 630, 6-iodo-2-methyl-1-[2-
(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone(6-iodopravadoline) (both
soluble in DMSO) were from Tocris Bioscience (Bristol, UK).
RNAiFect TM Transfection Kit was from Qiagen (Milan, Italy). Unless otherwise stated, all other
chemicals were purchased from Sigma (Milan, Italy). L-NAME (L-N G-nitroarginine methyl ester
(hydrochloride)) was dissolved in DMSO, and Pertussis toxin (PTX) and sodium nitroprusside
(SNP) were dissolved in distilled water. Drug and molecular target nomenclature conforms to
Alexander et al., 2013.
Animals
All animal care and experimental procedures conformed to the guidelines issued by the European
Council (86/609/EEC) and were approved by the local Animal Care and Ethics Committee. One-
day-old Balb/c mice were obtained from Charles River (Calco, Italy).
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Cell lines
The N9 murine microglial cell line (kindly donated by Dr P Ricciardi-Castagnoli, University of
Milan, Milan, Italy) was generated by infecting primary mouse microglial cultures with the J2
retrovirus carrying v-raf/v-myc oncogenes (Corradin et al., 1993). CHO cells transfected with the
human recombinant CB2 receptor cDNA (CHO-hCB2) were obtained from PerkinElmer (Milan,
Italy).
Primary microglial cell cultures
Primary glial cultures were prepared as described in a previous study (Molina-Holgado et al., 2002).
Briefly, after anesthesia (Zoletil 100, 30 mg·kg-1, Virbac Laboratories, France) and decapitation,
forebrains from newborn Balb/c mice were excised, meninges were removed and tissue was
dissociated mechanically. Cells were re-suspended in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin,
then plated on poly-D-lysine-coated (5 μg·mL-1) 75 cm2 flasks (Falcon; Celbio, Milan, Italy). After
15 days, the flasks were shaken vigorously to remove loosely adherent microglia. The supernatant
was plated on multi-well culture plates for 2 h, and the medium was changed to remove non-
adherent cells. Cells were grown in a humidified environment containing 5% CO2 at a constant
temperature of 37°C. The purity of microglial cultures was assessed by examining cell morphology
under phase-contrast microscopy and was confirmed by flow cytometry with Mac-1 anti-CD11b
antibody (BD Pharmingen, Milan, Italy).
Cell cultures
Cells were maintained in DMEM (primary and N9) or Ham’s (CHOh-CB2) medium containing 10%
fetal calf serum, penicillin (100 U·mL-1), streptomycin (100 μg·mL-1) and L-glutamine (2 mM) at
37°C in 5% CO2/95% air. Geneticin (G418, 0.4 mg·mL-1) was added to CHO-hCB2 cells. Cells were
split two or three times weekly at a ratio of 1:5 and 1:10.
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Flow cytometry of primary microglial cells
Aliquots of 0.5 x106 cells were incubated for 40 min at 4°C with either specific phycoerythrin (PE)-
labelled antibodies (Abs) or isotype-matched irrelevant IgG-PE (Beckman Coulter, Fullerton, CA)
as negative control. Cells were washed with PBS and characterized for expression of CD11b and
the glial fibrillary acidic protein (GFAP) by flow cytometry with PE-labelled anti-CD11b
monoclonal antibody (MoAb) (BD Pharmingen, Milan, Italy) and the fluorescein isothiocyanate
(FITC)-labelled anti-GFAP MoAb (BD Pharmingen). In particular, GFAP immunophenotyping was
performed in permeabilized cells, using IntraPrep™ fixing/permeabilization reagent (Beckman
Coulter) (Gobbi et al., 2003). Analysis was performed on an Epics XL flow cytometer (Beckman
Coulter) using Expo ADC software (Beckman Coulter).
Primary and N9 microglial cell exposure to cannabinoids and LPS treatment
LPS, a cell wall component of Gram-negative bacteria, is a potent activator of glia. Hence,
microglial cells were treated with 1 µg·mL-1 LPS (from Escherichia coli, serotype 055:B5,
dissolved in cell culture medium) before commencing incubation with cannabinoid ligands.
Microglia were then maintained in DMEM containing cannabinoids or their vehicle and harvested
after treatment at the indicated times.
Nitrite assay for primary microglial cells
NOS activity was assessed indirectly by measuring nitrite (NO2-) accumulation in the cell culture
media using a colorimetric kit (Calbiochem, Milan, Italy). At the end of the treatment period, the
nitrite concentration in the conditioned media was determined according to a modified Griess
method (Merighi et al, 2012). Briefly, the NADH-dependent enzyme nitrate reductase was used to
convert the nitrate to nitrite prior to quantification of the absorbance, measured at 540 nm by a
spectrophotometric microplate reader (Fluoroskan Ascent, Labsystems, Sweden). Sodium nitrite
was used as the standard compound.
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Western blotting in primary and N9 microglial cells
Western blot assay was performed as previously described (Merighi et al., 2009). Aliquots of total
protein sample (50 µg) were analyzed using antibodies specific for phosphorylated or total p44/p42
MAPK (1:5000 dilution), phosphorylated or total p38 (1:1000 dilution), phosphorylated or total
JNK 1/2 (1:1000 dilution) and for anti-CB2 receptor and anti-TLR4 sera. Specific reactions were
revealed with Enhanced Chemiluminescence Western blotting detection reagent (Amersham Corp.,
Arlington Heights, IL). The membranes were then stripped and re-probed with tubulin (1:250) to
ensure equal protein loading.
Densitometry analysis
The intensity of each immunoblot assay band was quantified using a VersaDoc Imaging System
(Bio-Rad, Milan, Italy). Mean densitometric data from independent experiments were normalized to
the results obtained with control cell cultures. The ratio of phospho-protein to total protein was
reported in a densitometric analysis. In particular, MAPK phosphorylation was expressed as ratios
between phosphorylated and total MAPK intensity (pMAPK/MAPK).
siRNA transfection of N9 microglial cells
Microglial cells were plated in six-well plates and grown to 50–70% confluence before transfection.
Transfection of siR-NACB2 or siRNATLR4 was performed at a concentration of 100 nM using
RNAiFectTM Transfection Kit (Qiagen). Cells were cultured in complete media, and total proteins
were isolated at 24, 48 and 72 h for Western blot analysis of CB2 and TLR4 receptor protein. A
randomly chosen non-specific siRNA was used under identical conditions as control (Merighi et al.,
2005; 2007).
Immunocytochemistry in cultured N9 microglial cells
Immunostaining was performed directly on cells seeded on glass coverslips. ERK-1 and ERK-2
were detected by anti-ACTIVE MAPK pAb, an affinity-purified rabbit serum that specifically
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recognizes the dual-phosphorylated active forms of MAP (also known as p44/ERK-1 and p42/ERK-
2) enzymes. Microglial cells were seeded on glass coverslips in 24-well plates overnight at 37°C in
a humidified atmosphere containing 5% CO2. Microglial cells were treated with 1µg·mL-1 LPS
alone or in combination with JWH-015. After 15 or 30 min, the medium was removed, and cells
were washed twice with PBS, mixed in 10% paraformaldehyde for 30 min, permeabilized in a PBS
solution containing 0.1% Triton X-100 and incubated for 30 min with PBS-plus 5% goat serum and
0.5% BSA. Cells were then stained (for 24 h at 4°C in a humidified chamber) with a 1:200 dilution
of anti-ACTIVE MAPK pAb in 0.5% of goat serum and 0.5% BSA PBS solution. Excess antibody
was washed away with PBS, and rabbit antibodies were detected with FITC-labelled goat anti-
rabbit IgG. Coverslips were stained with 4′,6′-diamino-2-phenyl-indole (DAPI), mounted in
DABCO glycerol-PBS and observed with a Nikon fluorescent microscope.
Data analysis
All values in the figures and text are expressed as mean ± SE of n observation (n  ≥ 3). For the
primary cell work, n is equal to the number of mice from which the cells were derived. Data sets




CB2 receptor expression in primary and N9 mouse microglial cells
Expression of the myeloid cell surface antigen CD11b was analyzed in primary microglial cells by
flow cytometry. Cells were treated with specific MoAbs or isotype-matched irrelevant MoAbs.
Microglia were negative for the astrocyte-specific protein GFAP but showed significant positive
staining for CD11b, as compared with the isotype control, thereby indicating high expression levels
of the microglial cell marker CD11b (Figure 3A).
The expression of CB2 cannabinoid receptor in CHO-hCB2 (used as positive control) in quiescent
and LPS-activated primary and N9 mouse microglial cells is illustrated in Figure 3. The molecular
weight of the protein detected in these cells was 50 kDa, comparable with the calculated molecular
weight of CB2 receptors. Expression of CB2 receptor protein was not modified by 30 min treatment
with LPS (1µg·mL-1; Figure 3B). 
To evaluate the previously reported effect of LPS-induced up-regulation of CB2 receptors, we
assayed CB2 receptors over 4 h of LPS treatment. In agreement with published data
(Mukhopadhyay et al., 2006), no significant increase in CB2 receptor immunoreactivity was
observed by Western blot in 4 h after LPS treatment (data not shown).
Effects of activating CB2 receptors on MAPKs in quiescent N9 microglial cells
The effects of CB2 cannabinoid receptor stimulation were studied using JWH-015, a cannabinoid
receptor agonist known to bind more readily to CB2 than CB1 receptors (Merighi et al., 2010), to
test whether CB2 receptors could induce ERK-1/2, p38 and JNK-1/2 phosphorylation in murine N9
microglial cells. As shown in Figure 4A, JWH-015 (10 nM) induced a rapid and sustained (up to 60
min) stimulation of ERK-1/2 and JNK-1/2. Conversely, p38 phosphorylation levels were not
affected.
We then set out to evaluate the concentration-dependent effects of JWH-015 on N9 cells treated for
10 min. As shown in Figure 4B, JWH-015 (10–1000 nM) increased p-ERK-1/2 and p-JNK-1/2
expression levels but did not modulate p-p38. Furthermore, addition of the antagonist AM 630 (0.1–
1 µM) blocked the JWH-015-induced (10–1000 nM) increase in ERK-1/2 and JNK-1/2
phosphorylation (Figure 5A,B). The CB1 receptor antagonist AM 251 (1 µM), on the other hand,
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had no effect on the increase in ERK-1/2 and JNK-1/2 phosphorylation levels induced by JWH-015
(1 µM; Figure 5B).
To further investigate the possible involvement of the Gi/Go-proteins in the signal transduction
pathway responsible for ERK-1/2 and JNK-1/2 modulation, N9 cells were treated with PTX (50
ng·mL-1). Blockade of Gi/Go-protein dissociation with PTX abolished the JWH-015-induced
activation of ERK-1/2 and JNK-1/2 in N9 cells (Figure 5C).
Effects of activating CB2 receptors on MAPKs in activated N9 and primary
microglial cells
We went on to investigate how the activation of microglial cells interferes with the signalling
pathways modulated by CB2 receptors by maintaining microglial N9 cells in LPS-supplemented (1
µg·mL-1) DMEM; the ability of JWH-015 (10 and 100 nM) to modulate MAPKs was evaluated
after 15 and 30 min. As shown in Figure 6A, LPS significantly increased all kinases under
investigation. In contrast, the CB2 receptor agonist JWH-015 failed to modulate the activity of LPS
on p38 and JNK-1/2 at any time, but p-ERK-1/2 levels in LPS-treated cells were increased at 15
min. Conversely, JWH-015 significantly decreased ERK-1/2 phosphorylation levels in LPS-
activated cells after 30 min of treatment (Figure 6A).
These results were confirmed in primary microglial cells, which yielded similar results to those
observed in N9 cells. In particular, as shown in Figure 6B, JWH-015 (100 nM) significantly
decreased ERK-1/2 phosphorylation levels in LPS-activated primary cells (after 30 min of
treatment).
Figure 6C shows that, in LPS-treated primary microglial cells, the CB2 antagonist AM 630 (1 µM)
abolished the effect of JWH-015 on ERK-1/2 phosphorylation, thereby confirming CB2 receptor
involvement. In contrast, the CB1 antagonist AM 251 (1 µM) did not reverse the ability of JWH-015
to down-regulate the LPS-induced increase in p-ERK-1/2 (Figure 6C).
We then studied the time-course of the effects of the CB2 receptor agonist on LPS signalling. As
shown in Figure 6D, LPS stimulation of microglial cells resulted in a rapid (after 15 min) increase
in ERK-1/2 phosphorylation, which was maximal at 30 min and declined towards basal levels
within 60 min. In the presence of the CB2 agonist JWH-015 (100 nM), on the other hand, ERK-1/2
phosphorylation was significantly higher at 15 min than with LPS alone. In contrast, ERK-1/2
phosphorylation levels were significantly reduced by LPS + JWH-015 at the 30 min incubation time
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point, as compared with LPS alone. Activation of ERK-1/2 returned to baseline levels within 120
min.
Finally, we studied the intracellular distribution of activated ERK-1 and ERK-2 MAPKs in N9 cells
during LPS (1 µg·mL-1) and JWH-015 (100 nM) treatment, alone and in combination, at 15 and 30
min. As seen in Figure 7, faint fluorescence caused by anti-ERK-1 and anti-ERK-2-activated
isoforms was detected in the cytoplasm of cells treated with drug vehicle, contrasting with the
strong fluorescence present in the nuclei of LPS- and JWH-015-treated cells after 15 and 30 min of
treatment. Activated ERKs were also detected in the nuclei of N9 cells after 15 min of treatment
with LPS in combination with JWH-015, but not after 30 min of combined treatment.
CB2 receptors modulate Raf-1 and MEK-1/2 kinases in quiescent N9 microglial
cells
We investigated the levels of p-ERK upstream effectors, namely, p-Raf-1 and p-MEK-1/2, after
CB2 receptor stimulation in N9 cells. A significant increase in p-Raf expression levels was noted
after 5 min of treatment with JWH-015 in the range 1–1000 nM (Figure 8A). The increase in Raf
phosphorylation was marked until 30 min but had disappeared entirely by 60 min. Interestingly, the
kinetics of Raf phosphorylation were comparable with those of ERK-1/2 phosphorylation.
Furthermore, the JWH-015-induced increase of Raf activity was blocked by the addition of the
selective CB2 antagonist AM 630 (0.1–1 µM) (Figure 8A).
An increase in MEK-1/2 phosphorylation in N9 cells was promptly (5 min) induced by JWH-015
(10–100 nM; Figure 8B), an effect that was prevented by the CB2 receptor antagonist AM 630 (0.1–
1µM) (Figure 8B).
p-Raf and p-MEK-1/2 levels were then evaluated in N9 cells treated with 1mg·mL-1 LPS for 5 and
20 min. LPS increased p-Raf and p-MEK-1/2 levels at 5 and 20 min of treatment, JWH-015 had no
effect on LPS activity at 5 min (Figure 8C), while CB2 receptor activation inhibited LPS stimulation
of Raf and MEK-1/2 after 20 min of treatment (Figure 8D). Moreover, the antagonist AM 630 (1
µM) blocked the ability of JWH-015 to decrease the LPS-modulated p-Raf and p-MEK-1/2
expression levels at 20 min (Figure 8D). Figure 8E shows that blockade of Gi/Go-protein
dissociation by PTX (50 ng·mL-1) abolished the ability of JWH-015 (10 and 100 nM) to impair
LPS-induced Raf, MEK-1/2 and ERK-1/2 phosphorylation.
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CB2 receptors modulate ERK-1/2 kinases by a NO-dependent pathway in
activated primary microglial cells
To define the signalling responsible for ERK-1/2 activation, downstream of CB2 receptors, in
microglia, quiescent and activated primary microglial cells were treated for 30 min with JWH-015
(100 nM) in the presence of the NOS inhibitor L-NAME (100 µM). Figure 9A shows that L-NAME
failed to alter the increased p-ERK-1/2 levels provoked by JWH-015, indicating that activation of
the CB2 receptor increased ERK activation in quiescent microglia cells in a NO-independent
manner. In contrast, L -NAME blocked the ability of JWH-015 to down-regulate LPS-induced ERK
activation in activated microglial cells, suggesting that CB2 receptor stimulation reduced the effects
of LPS on ERK-1/2 phosphorylation via a NO-mediated mechanism (Figure 9B).
To investigate the potential role of NO in LPS-mediated up-regulation of p-ERK-1/2, primary
microglial cells were treated with either LPS alone, LPS + JWH-015 (100 nM) or LPS + the NO
donor SNP (2.5 mM) for 30 min. As shown in Figure 9C, LPS significantly increased ERK-1/2
phosphorylation levels in primary microglial cells, an effect that was attenuated by JWH-015 and
also by SNP, thereby confirming that an excess of intracellular NO is sufficient to impair p-ERK
expression levels in primary microglial cells activated by LPS. In order to analyze iNOS protein
expression, primary microglial cells were then stimulated with LPS, with or without JWH-015, and
Western blotting was performed. As shown in Figure 9D, iNOS protein was induced after 4 h of
stimulation with LPS (1µg·mL-1). This induction was reduced by co-treatment with either JWH-015
or U0126 (0.5–1 µM).
Temporal conditions and concentrations of LPS required for optimal production of NO in primary
microglial cells were then defined. Nitrite levels were measured at 30 min and 4 h in culture
supernatants of microglial cells maintained in DMEM supplemented with LPS (1µg·mL-1; Figure
9E,F).
Primary microglial cultures were incubated with JWH-015 (0.5–1 µM) before and after LPS
activation. Different effects of CB2 receptor stimulation on nitrite levels were seen in quiescent
versus LPS-activated microglial cells. In the former, JWH-015 increased LPS-induced nitrite levels
at 30 min of treatment, when this increase was particularly significant (Figure 9E). In contrast, at 4
h, nitrite levels induced by LPS were decreased by CB2 receptor stimulation (Figure 9F).
Subsequently, the effect on nitrite release of pre-treatment of microglial cells with the CB2
antagonist AM 630 administered before exposure to JWH-015 was examined. 1 µM AM 630 alone
had no effect on microglial cell release of nitrite but did reverse the activity of JWH-015 (Figure
9E,F).
17
The effect on nitrite release of pre-treatment of microglial cells with U0126 (1 µM), a specific
inhibitor of MEK-1/2, the upstream regulator of ERK-1/2 phosphorylation, before exposure to LPS
and JWH-015 was investigated; U0126 administered alone had no effect on nitrite release by
microglial cells. Furthermore, in cells pre-treated with U0126, LPS for 30 min induced no
significant increase in nitrite levels, as compared with cells treated with LPS alone (Figure 9E),
indicating that LPS increased nitrite in an ERK-1/2-dependent manner. In contrast, the potentiating
effect of JWH-015 on LPS seen at 30 min was not abolished by U0126. There, unlike LPS, CB 2
receptor activation must increase NO production in microglial cells by ERK-independent signalling.
These data are in agreement with those reported in Figure 9B, which apparently shows p-ERK
downstream of NO in CB2-mediated signalling. At 4 h, JWH-015 reduced LPS-mediated NO
accumulation; this activity was mimicked by U0126, which suggests that, at 4 h, the effects of CB2
receptor stimulation in LPS-stimulated cells are consequent to the down-regulation of ERK-1/2
activation (Figure 9F).
Similar results were obtained with the MEK-1 inhibitor PD98059 in LPS- and JWH-015-treated cell
cultures (30 min and 4 h, data not shown).
CB2 and TLR4 receptor gene silencing in N9 cells
To confirm the apparent role of CB2 receptors and to investigate the involvement of TLR4, we
reduced CB2 and TLR4 receptor expression in N9 cells by siRNA transfection, in order to cause
transient knockdown of the CB2 and TLR4 receptor genes. N9 cells were transfected with non-
specific random control ribonucleotides (siRNA scrambled, siRNActr) or with small interfering
RNAs that targeted CB2 or TLR4 receptor mRNAs (siRNACB2 or siRNATLR4, respectively) for
degradation.
As seen in Figure 10A, CB2 receptor protein expression was strongly reduced after 48 and 72 h of
treatment with siRNACB2. Therefore, 48 h after siRNACB2 transfection, N9 cells were exposed to
LPS (1 µg·mL-1) and JWH-015 (100 nM) for 30 min, after which ERK-phosphorylated protein
levels were measured. This revealed that inhibition of CB2 receptor expression was sufficient to
block the JWH-015-induced inhibition of ERK-1/2 phosphorylation levels increased by LPS
(Figure 10B). These results clearly show the connection between CB2 receptor stimulation and ERK
signalling in activated microglial cells.
Likewise, Figure 10C shows that TLR4 receptor expression was reduced after 48 and 72 h of
treatment with siRNATLR4. Therefore, 72 h post-siRNATLR4 transfection, N9 cells were exposed to
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LPS (1µg·mL-1) and JWH-015 (100 nM) for 30 min. Inhibition of TLR4 receptor expression
blocked LPS-induced ERK-1/2 activation (Figure 10D). In contrast, JWH-015 significantly
increased ERK-1/2 phosphorylation levels even in the absence of TLR4, indicating that this agonist
acted in a TLR4-independent manner.
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Discussion and Conclusions
As microglial differentiation and immune function is regulated by activation of CB2 receptors
(Stella, 2010), we set out to characterize the signalling pathways modulated by these receptors
expressed in microglial cells. CB2 receptor ligands (agonist and antagonist) and CB2-receptor-
knockout microglial cells were thus used to determine the role of the cannabinoid system in in-vitro
models, using N9 and primary microglial cells. By this means we described the mechanism by
which CB2 cannabinoid receptors modulated the MAPK signalling in response to LPS, an agent
widely used experimentally to create inflammation in the brain (Lehnardtet al.,2002).
Multiple signalling molecules are activated in response to LPS in microglia (Aloisi, 2001). In
particular, while microglial cells display a quiescent phenotype in the normal brain, they become
highly activated upon insult, altering their phagocytic and antigen presentation functions, as well as
the production of cytokines and NO release (Lehnardt et al., 2002; Hanisch and Kettenmann, 2007).
Pathways associated with the induction of pro-inflammatory mediators of microglia include reactive
oxygen species, PI3K/Akt, MAPKs and NF-kB (Aloisi, 2001; Hanisch and Kettenmann, 2007).
The discrepancies between physiological microglia and microglial cell cultures, including primary
cultured microglia, have been much discussed (Horvathet al., 2008), and N9, being an artificially
immortalized cell line, may not entirely reflect the physiological functions of microglia. In an
attempt to clarify this situation, we compared mouse primary microglial and N9 cells in
experiments assessing the phosphorylation of ERKs and production and release of NO. As N9 cells
responded in a similar fashion to primary microglia, the cell line did, in our system, provide an
adequate model of primary microglia.
Moreover, in this study, we showed that CB2 cannabinoid receptors had different effects on ERK
activation in microglial cells, depending on the duration of cannabinoid exposure and the state of
cell activation. In particular, CB2 receptor stimulation increased ERK-1/2 phosphorylation levels in
quiescent and LPS-treated cells for 15 min, while, surprisingly, in the presence of both stimuli (LPS
and JWH-015), phosphorylation of ERK-1/2 was reduced following 30 min of treatment.
The signalling revealed in the presence of siRNACB2 confirmed the role of CB2 receptors in
microglial cells. Thus, we demonstrated that CB2 receptor stimulation provoked a state of activation
in microglial cells by rapid MAPK-phosphorylation but prevented over-activation in the presence of
a second stimulus.
It has been previously observed that CB2 receptor stimulation leads to ERK-mediated cellular
activation and anti-inflammatory effects in monocytes/macrophages and microglia (Gertsch et al.,
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2008; Correa et al., 2010). Furthermore, the endocannabinoid AEA has been shown to protect
neurones from inflammatory damage during CNS inflammation by rapid CB1/2-receptor-mediated
induction of MKP-1 in microglial cells (Eljaschewitsch et al., 2006). Hence, rapid AEA-induced
MKP-1 expression switches off MAPK signal transduction in activated microglial cells. Similarly, a
more recent study has demonstrated that CB2 receptor stimulation in microglial cells induces an
anti-inflammatory phenotype and reduces migration via MKP-induced ERK dephosphorylation
(Romero-Sandoval et al., 2009). Interestingly, here we show that the signalling observed in ERK-
1/2 kinase is reflected in Raf and MEK-1/2, thereby indicating that the CB2 receptor is coupled to
the activation of the ERK-1/2 kinase cascade through a classical upstream mechanism involving
Gi/Go-protein, Raf and MEK-1/2.
It has been reported that CB receptor agonists inhibit the production of pro-inflammatory
molecules, which can be induced by LPS, in CNS glial cells (Molina-Holgado et al., 2002;
Fachinetti et al., 2003; Ortega-Gutiérrez et al., 2005; Sheng et al., 2005; Correa et al., 2008; 2009).
In particular, CB2 receptors affect the production of the potent inflammatory mediator NO, released
from quiescent and, to a greater extent, from activated microglia (Stella, 2010). Here we
characterized, for the first time, the events occurring when quiescent microglia are exposed to LPS
and CB2 receptor agonist for 30 min, showing that CB2 receptor stimulation increased their response
to LPS without involving the TLR-4 pathway. Interestingly, at 15 and 30 min, the increase in ERK
activation and nitrite levels in response to LPS plus CB2 receptor stimulation was found to be
additive rather than synergistic. However, at 30 min, CB2 receptor stimulation was shown to reduce
LPS-induced ERK-1/2 increase in LPS activated microglia through modulation of NO production.
These data suggest that CB2 receptor stimulation alone activates the MAPK pathway but switches
off MAPK signal transduction by rapid induction of NO, in the presence of a second microglial
stimulus. Therefore, CB2 receptors expressed in microglia may participate in regulating
neuroinflammation and provide neuro-protection by tempering LPS-induced NO synthesis.
In agreement with previous reports that all three MAPK pathways are involved in iNOS gene
regulation in response to inflammatory stimuli in astrocytes and microglia (Bhat et al., 1998; Bodles
and Barger, 2005; Wang et al., 2006), we showed that CB2 receptor stimulation specifically reduced
iNOS activation via inhibition of ERK-1/2 phosphorylation. This indicates that inhibition of MAPK
pathways, and hence reduction in iNOS expression and NO production, is an important cellular
signalling cascade in glial cell activation, suggesting a functional inhibitory role for the cannabinoid
system in NO production. This accords with previous observations describing cannabinoid
responses in activated microglia and in macrophage-like cells (Stefano et al., 1996; Ross et al.,
2000; Walter et al., 2003; Ehrhart et al., 2005; Cabral et al., 2008; Kreitzer and Stella, 2009; Pietr et
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al., 2009; Oh et al., 2010). Indeed, endogenous or synthetic cannabinoids are known to inhibit LPS-
induced inducible NOS expression (mRNA and protein) through CB1 receptors in astrocyte
cultures. In addition, ∆9-tetrahydrocannabinol has been reported to produce a marked inhibition of
NO release in the macrophage cell line RAW 264.7 by inhibiting NF-kB/Rel activation and
increasing iNOS transcription (Jeon et al., 1996). Moreover, the CB1 receptor has been implicated
in the regulation of neuronal NOS in cerebellar granule neurons (Hillard et al., 1999). In cultured rat
microglial cells, on the other hand, inhibition of LPS/IFN-γ-induced NO release by the agonist CP-
55940 has been shown to act via a CB1 receptor-mediated pathway (Waksman et al.,1999).
However, in macrophages, the inhibition of LPS-mediated NO release by WIN-55212 occurs after
activation of CB2 receptors (Ross et al., 2000).
In addition, it has been recently reported that pharmacological stimulation of CB2 receptors and
manipulation of endocannabinoid tone, via inhibition of AEA hydrolysis in microglia, could result
in modification of the cytokine milieu, contributing to the accumulation of anti-inflammatory
microglia at lesion sites, in this case in multiple sclerosis (Correa et al., 2010). In particular, it has
been demonstrated that AEA inhibits the production of biologically active IL-12p70 and IL-23.
These cytokines play a crucial role in the pathogenesis of multiple sclerosis by activating human
(and murine) microglial cultures, acting through the ERK-1/2 and JNK pathways to down-regulate
IL-12p70 and IL-23 and up-regulate IL-10, effects that are partially mediated by CB2 receptor
activation (Correa et al., 2009; 2010).
Furthermore, it is well known that NO has an influence on critical signalling proteins; indeed,
exposure of cells to NO and NOS inhibitors has revealed their complex effects on the production of
cytokines. Precursors of IL-1β and IL-18 are not cleaved in the presence of NO, which also inhibits
the expression of IL-8 and MCP-1. In contrast, NO increased the release of TNF-α and IL-6 acting
simultaneously as a pro-inflammatory and anti-inflammatory agent (Murphy, 2000). Therefore, the
modulation of NO mediated by CB2 receptors may affect important target proteins in the CNS.
In conclusion, our results indicate a regulatory role for the CB2 receptor in preventing excessive
microglial cell response to injury in activated microglial cells. Hence, the development of selective
CB2 receptor agonists may open new avenues of therapeutic intervention, with the aim of reducing
the release of pro-inflammatory mediators, especially in chronic neuropathologies. This is
particularly exciting because selective CB2 receptor agonists are devoid of the psychoactive side
effects, characteristic of CB1 receptor activation in the CNS (Fernández-Ruiz et al., 2007;
Dhopeshwarkar et al, 2014).
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Figure Legends
Figure 3: Detection of CB2 cannabinoid receptors. (A) Cell surface expression of CD11b and
intracellular expression of GFAP by flow cytometry analysis. Primary microglial cells were treated
with specific MoAbs (grey histograms) or with isotype-matched irrelevant MoAbs (empty
histograms, controls). (B) CB2 receptor detection by Western blot assay in CHO-hCB2 cells, in
quiescent and LPS-activated (1 µg·mL-1 for 30 min) primary and N9 microglial cells. Tubulin
shows equal loading of protein.
Figure 4: Effects of stimulating CB2 cannabinoid receptors in N9 cells. (A) N9 cells were incubated
with 10 nM JWH-015 for the indicated time and ERK-1/2, p38 and JNK-1/2 phosphorylation levels
were analyzed by Western blot. (B) Western blot analysis of ERK-1/2, p38 and JNK-1/2
phosphorylation in N9 cells incubated for 30 min with JWH-015 (1–1000 nM). The immunoblot
signals were quantified using a VersaDoc Imaging System (Bio-Rad). MAPK phosphorylation was
expressed as ratios between phosphorylated and total MAPK intensity (pMAPK/MAPK). The mean
values of three independent experiments (one of which is shown) were normalized to the result
obtained with JWH-015-untreated cell cultures. Densitometric analysis is reported. The
unstimulated control (0, cells in the absence of JWH-015) was set to 100 %. *P < 0.05, significantly
different from unstimulated control; ANOVA followed by Dunnett’s test.
Figure 5: The CB2 cannabinoid receptor and the Gi/Go-protein pathway in N9 cells. (A) Western
blot analysis of p-ERK-1/2 and p-JNK-1/2 expression levels. N9 cells were incubated with JWH-
015 (10 and 100 nM) and AM 630 (0.1 and 1 µM) alone or in combination. (B) Western blot
analysis of p-ERK-1/2 and p-JNK-1/2 expression levels. N9 cells were incubated with JWH-015 (1
µM), AM 630 (1 µM) and AM 251 (1 µM), alone or incombination. (C) N9 cells were incubated
with or without PTX (50 ng·mL-1 for 14 h) and then with or without JWH-015 (10 and 100 nM) for
additional 10 min. The immunoblot signals were quantified using a VersaDoc Imaging System
(Bio-Rad). MAPK phosphorylation was expressed as ratios between phosphorylated and total
MAPK intensity (pMAPK/MAPK). Densitometric analysis is reported. The unstimulated control (0,
cells in the absence of JWH-015) was set to 100%. *P < 0.05, significantly different from
unstimulated control; ANOVA followed by Dunnett’s test.
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Figure 6: Effect of CB2 cannabinoid receptor stimulation in activated microglia cells. (A) JWH-015
effect on ERK-1/2, JNK-1/2 and p38 phosphorylation in N9 cells treated with LPS. N9 cells were
incubated with DMSO vehicle (lane 0) or with JWH-015 (10 and 100 nM) in the presence of LPS (1
µg·mL-1) for 15 and 30 min. (B) JWH-015 effect on ERK-1/2 phosphorylation in primary microglia
cells treated with LPS. Microglial cells were incubated with DMSO vehicle (lane 0) or with JWH-
015 (100 nM) in the presence of LPS (1 µg·mL-1 for 15 and 30 min). (C) Primary microglial cells
were incubated with DMSO vehicle (lane 1, control), LPS (1 µg·mL-1, lane 2), LPS + JWH-015
(100 nM), LPS + AM630 (1 µM; upper panel)/AM 251 (1 µM; lower panel) (lanes 3 and 4,
respectively), and with LPS + JWH-015 + AM 630/AM 251 (lane 5) for 30 min. (D) Time-
dependent pERK-1/2/MAPK phosphorylation induced by LPS (1 µg·mL-1) and LPS + JWH-015
(100 nM) after 0, 15, 30, 60 and 120 min. The mean values of three independent experiments (one
of wich is shown) were normalized to the result obtained in cells in the absence of LPS. Plots are
mean ± SE values (n = 3). The unstimulated control (0) was set to 100%. The immunoblot signals
were quantified using a VersaDoc Imaging System (Bio-Rad). Densitometric analysis of MAPK
activation is shown as the ratio of phospho-protein to total protein. *P < 0.05 significantly different
from untreated cells; #P < 0.05 significantly different from cells treated with LPS alone; ANOVA
followed by Dunnet’s test.
Figure 7: Intracellular localization of pERK-1/2. N9 cells (untreated cells, ctr) were treated with
LPS (1 µg·mL-1) alone or in combination with JWH-015 (100 nM) for 15 or 30 min. Cells were
then stained with antibody to ERK-1/2 phosphorylated isoforms and detected by goat FITC anti-
rabbit IgG. The fluorescent dye DAPI (blue panel) was used to stain the nuclei of all microglial
cells. Overlap of DAPI and FITC is shown (right panels). Original magnification, 40x.
Figure 8: CB2 cannabinoid receptors modulate Raf and MEK-1/2 phosphorylation in quiescent (A–
B) and activated (C–E) N9 cells. Cells were incubated with 10 nM JWH-015 for the indicated time
(from 0 to 60 min) or for 30 min with different concentrations of JWH-015 (1–1000 nM). Raf (A)
and MEK-1/2 (B) kinase phosphorylation levels were quantified by Western blot analysis.
Furthermore, N9 cells were incubated with JWH-015 (10 and 100 nM). AM 630 (0.1 and 1µM) was
added alone or in the presence of JWH-015 (10 and 100 nM) before determination of Raf (A) and
MEK-1/2 (B) phosphorylation. N9 cells were treated with LPS (1 µg·mL-1) for 5 (C) or 20 (D) min.
The effect of the antagonist AM 630 (1 µM) is shown. (E) N9 cells were incubated with or without
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PTX (50 ng·mL-1 for 14 h) and then with or without LPS (1 µg·mL-1) alone or in combination with
JWH-015 (10 and 100 nM) for additional 30 min. The immunoblot signals were quantified using a
VersaDoc Imaging System (Bio-Rad). The mean values of three independent experiments (one of
which is shown) were normalized to the result obtained in cells in the absence of JWH-015.
Densitometric analysis is shown as the ratio of phospho-protein to total protein. The unstimulated
control (0, cells in the absence of JWH-015) was set to 100%. *P < 0.05, significantly different
from unstimulated control; analysis was by ANOVA followed by Dunnett’s test.
Figure 9: The CB2 cannabinoid receptor and the NO pathway in primary microglial cells. (A)
Primary microglial cells were incubated with DMSO vehicle (lane 1, control), L-NAME (100 µM;
lanes 2, 4) and with JWH-015 (100 nM; lanes 3–4). (B) Primary microglial cells were incubated
with DMSO vehicle (lane 1, control), LPS (1 µg·mL-1; lane 2) and with JWH-015 (100 nM; lanes
4–5) or L-NAME (100 µM lanes 3, 5) for 30 min. (C) Primary microglial cells were incubated for
30 min with DMSO vehicle (lane 1) or LPS (1 µg·mL-1; lanes 2–4), JWH-015 (100 nM; lane 3) or
SNP (2.5 mM; lane 4). The immunoblot signals were quantified using a VersaDoc Imaging System
(Bio-Rad). The mean values of three independent experiments (one of which is shown) were
normalized to the result obtained in cells in the absence of LPS. Densitometric analysis is reported
as the ratio of phospho-protein to total protein. The unstimulated control was set to 100%. *P < 0.05
with respect to unstimulated control; #P < 0.05, significantly different from cells treated with LPS
alone; **P < 0.05, significantly different from LPS + JWH-015; ANOVA followed by Dunnett’s
test. (D) Primary microglial cells were treated with LPS (1 µg·mL-1) for 4 h without and with JWH-
015 (0.5 and 1 µM) to assess the effect on iNOS levels. These cells were harvested for Western
analysis of iNOS expression. The mean values of three independent experiments (one of which is
shown) were normalized to the result obtained in cells in the absence of LPS. The unstimulated
control was set to 100%. *P < 0.05, significantly different from unstimulated control; #P < 0.05,
significantly different from cells treated with LPS alone; ANOVA followed by Dunnett’s test. (E–
F) Effect of LPS and CB2 receptor stimulation on nitrite levels in microglial cells. Primary
microglial cells were treated with JWH-015 (0.5 and 1 µM), with or without LPS (1 µg·mL-1) and
culture supernatants were assayed for nitrite after 30 min (E) and 4 h (F) of treatment. The effects of
U0126 (1 µM) and of AM 630 (1 µM) are shown. *P < 0.01, significantly different from untreated
cells; #P < 0.05, significantly different from LPS-treated cells. *P < 0.01, significantly different
from untreated cells; #P < 0.05, significantly different from LPS-treated cells; ANOVA followed by
Dunnett’s test.
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Figure 10: CB2 and TLR4 receptor expression silencing. (A) N9 microglial cells were treated with
scrambled (-) (control) or with siRNACB2 (+) and cultured for 24, 48 and 72 h. Tubulin shows equal
loading of protein. Densitometric quantification of CB2 receptors by Western blot; plots are mean ±
SE values (n = 3); *P < 0.01, significantly different from the control (scrambled transfected cells).
(B) N9 microglial cells were treated with siRNACB2 or without (control) siRNACB2 for 48 h and
cultured with LPS (1 µg·mL-1) alone or in combination with JWH-015 (100 nM) for 30 min.
Densitometric analysis of phosphorylated isoform is shown as the ratio of phospho-protein to total
protein. The immunoblot signals were quantified using a VersaDoc Imaging System (Bio-Rad). The
mean values of three independent experiments (one of which is shown) were normalized to the
result obtained in cells in the absence of LPS. The unstimulated control was set to 100%. *P < 0.05,
significantly different from unstimulated control; #P < 0.05, significantly different from cells treated
with LPS alone; ANOVA followed by Dunnett’s test. (C) N9 microglial cells were treated with
scrambled (-) (control) or with siRNATLR4 (+) and cultured for 24, 48 and 72 h. Tubulin shows equal
loading of protein. Densitometric quantification of TLR4 receptor by Western blot; plots are mean
± SE values (n = 3); *P < 0.01 compared with the control (scramble transfected cells). (D) N9
microglial cells were treated with siRNATLR4 or without (control) siRNATLR4 for 72 h and cultured
with LPS (1 µg·mL-1) alone or in combination with JWH-015 (100 nM) for 30 min. Densitometric
analysis of phosphorylated isoform is reported as the ratio of phospho-protein to total protein is
used. The immunoblot signals were quantified using a VersaDoc Imaging System (Bio-Rad). The
mean values of three independent experiments (one of which is shown) were normalized to the
result obtained in cells in the absence of LPS. The unstimulated control was set to 100%. *P < 0.05,
significantly different from unstimulated control; #P < 0.05, significantly different from cells treated
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inflammatory responses in activated microglial cells
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Introduction
Interactions between opioids and cannabinoids
Opioids and cannabinoids are two classes of drugs that share numerous similar pharmacological
effects, including sedation, analgesia, euphoria, inhibition of the intestinal motility, locomotor
activity, and suppression of immune function. However, the most important interactions were found
in antinociception and, to lesser extent, in drug reinforcement (Manzanares et al., 1999).
Opioids constitute a large family of compounds with different chemical natures (from peptides to
alkaloids). They produce their pharmacological effects by acting mainly through three types of
receptors, namely μ, δ and κ (Satoh and Minami, 1995; receptor nomenclature follows Alexander
et al., 2011). They bind endogenous opioid peptides including enkephalins, endorphins and
dynorphins. In clinical practice, opioids are considered mainly as analgesics; however, they play an
important role as neuroregulators of a number of central and peripheral tissues, including
immunomodulation, respiration, behavior, and gastrointestinal motility. Pharmacological
overdosing may result in side effects that include respiratory depression, miosis, serenity, urinary
retention, vomiting, pruritus, dyspnea, sedation, euphoria, dysphoria, or psychomimetic effects
(Lazarczyk et al., 2010). Opioids are the drugs of choice for treating severe pain, despite the
development of tolerance, dependence and hyperalgesia (da Fonseca Pacheco et al., 2008). The
cellular and molecular mechanisms involved in this phenomenon are complex and may involve
receptor desensitization and endocytosis, intracellular signalling hyperactivity, secondary activation
of excitatory amino acid receptors, and subsequent intracellular cascades as well as glial activation
and the release of proinflammatory mediators (Mayer et al., 1999; Watkins et al., 2005). Glial
activation by opioids is an important phenomenon to understand, as it opposes opioid analgesia and
enhances opioid tolerance, dependence and other negative side-effects, such as respiratory
depression (Watkins et al., 2009). In particular, there is good evidence that glia and glia-derived
proinflammatory mediators, such as IL-1β, TNF-α, and IL-6, could be involved in tolerance to anti-
nociceptive properties of morphine. Glial cells are also considered to be crucial sources of nitric
oxide (NO), responsible for morphine tolerance (Mayer et al., 1999; Chen and Sommer, 2009).
Repeated morphine treatment can activate glia and hence up-regulate these various mediators
(Raghavendra et al., 2002; 2004; Johnston et al., 2004; Watkins et al., 2005) through the MAPK,
PKC and PI3K/Akt pathways, key players in the intracellular signalling cascade leading to the
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development of morphine tolerance (Mayer et al., 1999; Watkins et al., 2001; Raghavendra et al.,
2002, 2004; Galeotti et al., 2006; Cunha et al., 2010).
In the nervous system, neurotransmission and neuroinflammation are mediated by the
endocannabinoid signalling system (Fernández-Ruiz, 2009; Marrs et al., 2010). To date, two
cannabinoid receptors have been identified by molecular cloning - CB1 and CB2 receptors. The CB1
receptors are expressed by the neurons and regulate the release of neurotransmitters, while CB 2
receptors are expressed by the microglia, regulating their motility and immunomodulator production
(Atwood and Mackie, 2010; Pertwee et al., 2010). In the nervous system, activation of CB1 and CB2
receptors is induced by the endocannabinoids, arachidonoylethanolamide (anandamide, AEA) and
2-arachidonoylglycerol produced by the neurons and glia (Massi et al., 2013). However, ample
evidence suggests that additional receptors may contribute to the behavioral, vascular and
immunological actions of Δ9-tetrahydrocannabinol (THC), the major psychoactive constituent of
marijuana, and endocannabinoids (Begg et al., 2005). In particular, it has been established that
GPR55 is an additional novel cannabinoid receptor (Lauckner et al., 2008; Bondarenko 2014).
Microglia, a specialized population of macrophages found in the CNS, are quiescent in normal
brain. However, after CNS injury or after interaction of LPS with toll-like receptor (TLR)-4 during
bacterial infection (González-Scarano and Baltuch, 1999), these cells can be activated by cytokines
produced by infiltrating immune effector cells. Activated microglia can promote neuroinflammatory
response throught the release of inflammatory mediators, including IL-1β, TNF-α, prostaglandin E2
(PGE2), and NO (Grace et al., 2014). Thus, LPS stimulation of the microglia is a useful model for
the study of mechanisms underlying neuronal injury by various proinflammatory and neurotoxic
factors released by activated microglia (Jung et al., 2010). 
CB receptor agonists produce pain relief in a variety of animal models (Richardson, 2000).
Cannabinoids act on glia and neurons to inhibit the release of proinflammatory molecules, including
IL-1β, TNF-α, and NO (Molina-Holgado et al., 1997; 2002; Shohami et al., 1997; Puffenbarger et
al., 2000; Cabral et al., 2001), and enhance the release of the anti-inflammatory cytokines IL-4, IL-
10 (Klein et al., 2000), and IL-1 receptor antagonist (Molina-Holgado et al., 2003). It is known that
the anti-inflammatory properties of CB receptor agonists are expressed through the activation of
CB2 receptors (Klein and Newton, 2007; Romero-Sandoval et al., 2009; Correa et al., 2010; Hsieh
et al., 2011). In particular, the activation of CB2 receptors expressed in brain microglia during
neuroinflammation (Benito et al., 2008; Atwood and Mackie, 2010) reduced NO production and
TNF-α in primary microglia (Ehrhart et al., 2005; Merighi et al., 2012a). Furthermore, such
activation protects against human microglial neurotoxicity by enhancing IL-10 production (Klegeris
et al., 2003; Correa et al., 2005; 2010; Eljaschewitsch et al., 2006). The activation of CB2 receptors
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also reduces the release of proinflammatory factors in animal models of peritoneal hypoxia-
ischemia and Huntington’s disease (Benito et al., 2008). In the periphery, both CB1 and CB2
receptors participate in pain control (Malan et al., 2001).
Interestingly, receptors for opioids and cannabinoids are coupled to similar intracellular signalling
mechanisms, leading to a decrease in cAMP production through the activation of Gi proteins (Satoh
and Minami, 1995; Pertwee et al., 2010). Therefore, following the discovery that opioids and
cannabinoids produce not only similar biochemical effects but also similar pharmacological effects,
the interaction between these two classes of drugs has been studied (Manzaneres et al., 1999).
Cannabinoids can enhance the antinociceptive properties of opioids (Cichewicz, 2004; Wilson et
al., 2008; Parolaro et al., 2010) and adolescent exposure to chronic THC blocks opiate dependence
in maternally deprived rats (Morel et al., 2009). However, the molecular signalling underlying the
participation of cannabinoids in the side effects induced by opioids is still unknown. Nevertheless, it
is possible that cannabinoids may interfere with the tolerance and dependence effects induced by
opioids because the administration of low-dose combinations of cannabinoids and opioids seems to
be an alternative regimen that reduces the need to escalate opioid dose, while increasing opioid
potency.
Therefore, the aim of the present study was to explore whether and how CB2 receptor stimulation
affected opioid actions on activated microglia, with a view to improving pain control by increasing




All animal care and experimental procedures conformed to the guidelines issued by the European
Council (86/609/EEC) and were approved by the local Animal Care and Ethics Committee. The
results of all studies involving animals are reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals (McGrath et al., 2010). One-day-old Balb/c mice (50 in
total) were obtained from Charles River (Calco, Italy).
Cell line, reagents and antibodies
CHO cells transfected with the human recombinant CB2 receptor cDNA (CHO-hCB2) were
purchased from PerkinElmer (Milan, Italy). Tissue culture media and growth supplements were
obtained from Cambrex, Bergamo, Italy. U0126 (MEK-1 and MEK-2 inhibitor, soluble in DMSO);
human anti-ACTIVE®MAPK (phosphorylated Thr183/Tyr185) and human anti-ERK1/2 pAb were
provided by Promega (Milan, Italy). Phosphorylated (Thr180/Tyr182) and total p38, phosphorylated
(Thr183/Tyr185) and total JNK1/2 antibodies were from Cell Signalling Technology (Celbio, Milan,
Italy). JWH-015 (1-propyl-2-methyl-3-(1-naphthoyl)indole) (soluble in ethanol), SH5 (inhibitor of
Akt), blocking peptide for pAb to CB2 receptor (ALX-153-027) and anti-CB2 receptor rabbit
polyclonal antibody (ALX-210-198) were from Enzo Life Sciences (Vinci-Biochem, Florence,
Italy). The immunogen for the CB2 receptor antibody was a synthetic peptide corresponding to aa
20–33 of the human CB2 receptor N-terminal. Anti-MOR-1 (H80) (sc-15310), small interfering
RNA (siRNA) for the CB2 receptor (sc-39913) and MOR-1 siRNA (sc-35958) were from Santa
Cruz Biotechnology (DBA, Milan, Italy). AM 251 (N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-
iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide) and AM 630 (6-iodo-2-methyl-1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (6-iodopravadoline) (both soluble
in DMSO) were from Tocris Bioscience (Bristol, UK). RNAiFect™ Transfection Kit was from
Qiagen (Milan, Italy). Unless otherwise stated, all other chemicals were purchased from Sigma
(Milan, Italy). Drug and molecular target nomenclature conforms to Alexander et al., 2013.
46
Primary microglial cell cultures
Primary glial cultures were prepared as described in a previous study (Molina-Holgado et al., 2002).
Briefly, after anesthesia (Zoletil 100, 30 mg·kg-1, Virbac Laboratories, Carros, France) and
decapitation, forebrains from newborn Balb/c mice were excised, meninges removed and tissue
dissociated mechanically. Cells were re-suspended in DMEM supplemented with 10% heat-
inactivated FBS and 1% penicillin/streptomycin, then plated on poly-D-lysine-coated (5 μg·mL-1)
75 cm2 flasks (Falcon; Celbio, Milan, Italy). After 15 days, the flasks were shaken vigorously to
remove loosely adherent microglia. The supernatant was plated on multi-well culture plates for 2 h,
and the medium was changed to remove non-adherent cells. Cells were grown in a humidified
environment containing 5% CO2 at a constant temperature of 37°C. The purity of microglial
cultures was assessed by examining cell morphology under phase-contrast microscopy, and was
confirmed by flow cytometry with Mac-1 anti-CD11b antibody (BD Pharmingen, Milan, Italy).
Cell cultures
Cells were maintained in DMEM (primary microglia) or Ham’s (CHOh-CB2 cells) medium
containing 10% fetal calf serum, penicillin (100 U·mL-1), streptomycin (100 μg·mL-1), and L-
glutamine (2 mM) at 37°C in 5% CO2/95% air. Geneticin (G418, 0.4 mg·mL-1) was added to CHO-
hCB2 cells. Cells were split two or three times weekly at a ratio between 1:5 and 1:10.
Flow cytometry of primary microglial cells
Aliquots of 0.5 x 106 cells were incubated for 40 min at 4°C with either specific phycoerythrin
(PE)-labelled antibodies, or isotype-matched irrelevant IgG-PE (Beckman Coulter, Fullerton, CA,
USA) as negative control. Cells were washed with PBS and characterized for CD11b and glial
fibrillary acidic protein (GFAP) expression by flow cytometry with PE-labelled anti-CD11b MoAb
(BD Pharmingen) and the fluorescein isothiocyanate (FITC)-labelled anti-GFAP MoAb (BD
Pharmingen). In particular, GFAP immunophenotyping was performed in permeabilized cells, using
IntraPrep™ fixing/permeabilization reagent (Beckman Coulter) (Gobbi et al., 2003). Analysis was
performed on an Epics XL flow cytometer (Beckman Coulter) using Expo ADC software (Beckman
Coulter).
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Primary microglial cell exposure to cannabinoids, opioids and LPS treatment
LPS, a cell wall component of Gram-negative bacteria, is a potent activator of glia. Hence,
microglial cells were treated with 1 μg·mL-1 LPS (from Escherichia coli, serotype 055:B5) (soluble
in cell culture medium) before commencing incubation with CB and opioid receptor ligands. Unless
otherwise stated, the concentration of morphine (Salars, Como, Italy), naloxone, Tyr-DAla-Gly-
[NMePhe]-NH(CH2)2 (DAMGO), cyc[DPen2, DPen5]enkephalin (DPDE), 5α,7α, 8β- (-) -N-methyl-
N-(7-[1-pyrrolidinyl]-1-oxasipro(4,5)dec-8-yl)benzeneacetamide (U69593), D-Phe-cyc[Cys-Tyr-D-
Trp-Arg-Thr-Pen]-Thr-NH2 (CTAP), JWH-015 (Enzo Life Sciences, Vinci-Biochem, Vinci,
Florence, Italy), AM 630 and AM 251 was 100 nM, which is the ligand concentration able to
occupy 99% of the receptors at equilibrium. Microglia were then maintained in DMEM containing
cannabinoids, opioids or their vehicle, and harvested after treatment at the indicated times.
Nitrite assay for primary microglial cells
NO synthase activity was assessed indirectly by measuring nitrite (NO2-) accumulation in the cell
culture media using a colorimetric kit (Calbiochem, Milan, Italy). At the end of the treatment
period, the nitrite concentration in the conditioned media was determined according to a modified
Griess method (Merighi et al., 2012b). Briefly, the NADH-dependent enzyme nitrate reductase was
used to convert the nitrate to nitrite prior to quantification of the absorbance, measured at 540 nm
by a spectrophotometric microplate reader (Fluoroskan Ascent Labsystems, Stockholm, Sweden).
Values were obtained by comparison with reference concentrations of sodium nitrite.
ELISA
The levels of IL-1β, TNF-α and IL-6 protein secreted by the cells in the medium were determined
by ELISA kits (R&D Systems). In brief, subconfluent cells were changed into fresh medium in the
presence of solvent or various concentrations of drugs. The medium was collected, and IL-1β, TNF-
α and IL-6 protein concentrations were measured by ELISA according to the manufacturer’s
instructions. The results were normalized to the number of cells per plate. The data are presented as
mean ± SE from four independent experiments performed in triplicate.
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Western blotting for primary microglial cells
Western blot assay was performed as previously described (Merighi et al., 2009). Aliquots of total
protein sample (50 μg) were analysed using antibodies specific for phosphorylated or total p44/p42
MAPK (1:5000 dilution), phosphorylated or total p38 (1:1000 dilution), phosphorylated or total
JNK1/2 (1:1000 dilution), phosphorylated or total Akt (1:1000 dilution), for CB2 and μ-opioid
receptors. Specific reactions were revealed with enhanced chemiluminescence Western blotting
detection reagent (Amersham Corp., Arlington Heights, IL, USA). The membranes were then
stripped and re-probed with tubulin (1:250) to ensure equal protein loading.
Densitometry analysis
The intensity of each immunoblot assay band was quantified using a VersaDoc Imaging System
(Bio-Rad, Milan, Italy). Mean densitometric data from independent experiments was normalized to
the results obtained with control cell cultures. The ratio of phospho-protein to total protein was
reported in a densitometric analysis.
Treatment of primary microglial cells with siRNA
Microglial cells were plated in six-well plates and grown to 50–70% confluence before transfection.
Transfection of siRNACB2 or siRNAμ was performed at a concentration of 100 nM using
RNAiFect™ Transfection Kit (Qiagen). Cells were cultured in complete media and total proteins
were isolated at 24, 48 and 72 h for Western blot analysis of CB2 and μ-opioid receptor protein. A
randomly chosen non-specific siRNA was used under identical conditions as control (Merighi et al.,
2005; 2007).
Statistical analysis
All data are reported as mean ± SEM of independent experiments and are indicated in the figure
legends. Each experiment was performed by using the microglial cells derived from one single
mouse, and was performed in triplicate. The experiments were repeated at least four times as
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indicated from n values that represent the number of mice used. Data sets were examined by
ANOVA for comparisons between multiple groups and Dunnett’s test for comparing a control




CB2 and µ-opioid receptor expression in primary mouse microglial cells
The expression of the myeloid cell surface antigen CD11b was analyzed in primary microglial cells
by flow cytometry. Cells were treated with specific MoAbs or isotype-matched irrelevant MoAbs.
Microglia were negative for the astrocyte-specific protein GFAP but showed significant positive
staining for CD11b, as compared to the isotype control, thereby indicating high expression levels of
the microglial cell marker CD11b (Figure 11A).
The expression of CB2 receptors in CHO-hCB2 cells (used as positive control), in quiescent and
LPS-activated primary microglial cells is shown in Figure 11B. The molecular weight of the protein
detected in these cells was 50 kDa, comparable with the calculated molecular weight of CB2
receptors. To ascertain the specificity of the CB2 receptor antibody used in Western blots, antigen
preabsorption experiments were carried out with the corresponding blocking peptide. Co-incubation
with the immunizing peptide completely prevented the signal (data not shown). CB2 receptor
protein expression was not modified by 30-min treatment with 1 µg·mL- 1 LPS (Figure 11B).
Similarly, the expression of µ-opioid receptors in mouse brain extracts (used as positive control) in
quiescent and LPS-activated primary microglial cells is shown in Figure 11B. Therefore, CB2 and
µ-opioid receptors were expressed in primary mouse microglial cells. To evaluate whether LPS
induced changes in CB2 receptor expression, we assayed CB2 receptors over 24 h of LPS treatment.
In agreement with published data (Carlisle et al., 2002), LPS 1 µg·mL-1 produced a time-dependent
increase in CB2 receptor expression over the period from 6 to 24 h (Figure 11C).
Effect of opioid receptor ligands on cytokine and nitrite production in primary
microglial cells
To investigate the effect of opioid receptor ligands on microglial activation, the ability of morphine
to induce inflammatory mediator production, such as IL-1β, TNF-α, IL-6 and nitrite, was examined
in LPS-stimulated microglial cells. The TLR-4 agonist LPS was used to induce IL-1β, TNF-α, IL-6
and NO (as nitrite) release from primary microglial cells. Preliminary studies in our laboratory
demonstrated that LPS induced release of these mediators from primary microglial cells in a
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concentration-dependent manner, with maximum release occurring at a concentration of 1 μg·mL-1
(data not shown). As shown in Figure 12, non-stimulated microglial cells showed a very low level
of IL-1β, TNF-α, IL-6 and nitrite but LPS triggered a robust increase in the release of these
mediators into the culture media. Then, we went on to investigate how the activation of opioid
receptors interferes with the signaling pathways modulated by LPS by maintaining primary
microglial cells in LPS-supplemented (1 μg·mL-1) DMEM in combination with the opioid receptor
agonist morphine (100 nM) for 24 h. As shown in Figure 12, LPS-induced cytokine and nitrite
release was significantly increased in the presence of morphine in primary microglial cells. The
stimulatory response of morphine on cytokine and nitrite production was reversed in the presence of
the broad-range opioid receptor-antagonist naloxone (Figure 12). Furthermore, DAMGO (100 nM),
a μ-opioid receptor-selective agonist, mimicked the effects of morphine on microglial cytokine and
nitrite induction (Figure 12). Conversely, DPDPE and U-69593, δ- and κ-receptor-selective
agonists, respectively, had no effect on LPS-induced microglial cytokine and nitrite production
(Figure 12). Finally, pretreatment of microglial cells with CTAP (100 nM), a selective antagonist of
μ-opioid receptors, before treatment with morphine (100 nM) or DAMGO (100 nM), abolished the
effects of opioid receptor agonists on LPS-induced cytokine and nitrite production by microglia
(Figure 12).
Influence of CB2 receptors on µ-opioid receptor-induced cytokine and nitrite
production in primary microglial cells
The effect of CB2 receptor stimulation on μ-opioid receptor induced cytokine and nitrite production
in primary microglial cells was studied using JWH-015, a CB receptor agonist known to bind more
readily to CB2 than CB1 receptors (Merighi et al., 2010). By this means we tested whether CB2
receptors can modulate cytokine and nitrite production in activated microglial cells. As shown in
Figure 13, JWH-015 (100 nM) significantly decreased LPS-induced IL-1β, TNF-α, IL-6 and nitrite
levels. Furthermore, co-administration of LPS (1 μg·mL-1), morphine (100 nM) and JWH-015 (100
nM) significantly attenuated the morphine-induced increases in cytokine and nitrite production
(Figure 13). The anti-inflammatory response of JWH-015 in LPS-activated microglial cells treated
with morphine was reversed in the presence of the CB2 receptor antagonist AM 630 (100 nM)
(Figure 13). In contrast, the CB1 antagonist AM 251 (100 nM) did not affect the ability of JWH-015
to down-regulate the increase in IL-1β, TNF-α, IL-6 and nitrite induced by morphine in LPS-
activated microglial cells (Figure 13).
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Signalling induced by morphine on quiescent and activated microglial cells
We went on to investigate whether the stimulatory effect of morphine on cytokine and nitrite
release induced by LPS is mediated via the MAPK and Akt pathways. We tested whether morphine
could induce ERK1/2, p38, JNK1/2 and Akt phosphorylation in primary murine microglial cells,
treated for 30 min at 37°C, in a concentration-dependent manner. As shown in Figure 14A,
morphine (1–1000 nM) increased p-ERK1/2 and pAkt expression levels but did not modulate pp38
and pJNK1/2. In particular, morphine (100 nM) induced a rapid and sustained (up to 60 min)
stimulation of ERK1/2 and pAkt (Figure 14B). Furthermore, we have investigated how the
activation of microglial cells interferes with the signalling pathways modulated by morphine. Thus,
microglial cells were maintained in DMEM containing LPS (1 µg·mL -1), and the ability of
morphine (100 nM) to modulate ERK1/2 and Akt phosphorylation was evaluated at 15, 30 and 60
min. As shown in Figure 14B, LPS stimulation of microglial cells resulted in a rapid (15 min)
increase in ERK1/2 and Akt phosphorylation, which was maximal at 30 min and declined towards
basal levels within 60 min. In the presence of morphine (100 nM), ERK1/2 and Akt
phosphorylation were significantly higher than LPS alone. To evaluate whether the morphine-
induced changes in ERK1/2 and Akt phosphorylation levels were μ-opioid receptor-dependent, we
used the selective antagonist of μ-opioid receptors, CTAP. Primary microglial cells were pretreated
with CTAP, then exposed to morphine for 30 min. Morphine-induced p-ERK1/2 and p-Akt
increased levels were reduced with CTAP pretreatment (Figure 14C), indicating that the effect of
morphine was mediated via the µ-opioid receptor subtype.
Signalling induced by morphine and JWH-015 on LPS-activated microglial cells
Primary microglial cells were treated with either LPS alone, LPS + JWH-015 (100 nM) or LPS +
morphine (100 nM) for 30 min. As shown in Figure 15, LPS significantly increased all kinases
measured. Furthermore, while the CB2 receptor agonist JWH-015 failed to modulate the activity of
LPS on p38 and JNK1/2, it significantly decreased ERK1/2 and Akt phosphorylation levels in LPS-
activated cells (Figure 15). Similarly, the phosphorylation of ERK1/2 and Akt were significantly
increased by morphine (100 nM) added LPS-activated cells, compared with treatment with LPS
alone. In contrast, morphine did not modulate LPS-induced phosphorylation of p38 and JNK
(Figure 15). Finally, when microglial cells were treated with LPS (1 μg·mL-1) plus morphine (100
nM) in combination with JWH-015 (100 nM), we found that JWH-015 decreased ERK1/2 and Akt
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activation induced by LPS plus morphine, without affecting pp38 and pJNK1/2 levels (Figure 15).
The effect of morphine and JWH-015 on ERK1/2 and Akt activation was reversed in the presence
of the antagonists naloxone and AM 630 respectively (Figure 16). In contrast, the CB1 receptor
antagonist AM 251 (100 nM) did not reverse the ability of JWH-015 to down-regulate the increase
in p-ERK1/2 and p-Akt induced by morphine (Figure 16).
Akt and MEK-1/2 inhibition decreases LPS-induced inflammatory effects in
microglial cells
To elucidate the mechanisms involved in the effects of morphine and JWH-015 on citokine and
nitrite production by activated microglial cells, we investigated the effects of inhibiting ERK1/2 or
Akt signalling pathways, with the MEK1/MEK2 inhibitor U0126 (1 μM) or the Akt inhibitor SH-5
( 1 μM). To confirm the activity of these inhibitors, primary microglial cells were treated with
U0126 (1 μM) and with SH-5 (1 μM) for 30 min and ERK-1/2 or Akt activation were measured.
We observed that 30 min incubations of microglial cells with either U0126 or SH-5 resulted in
significant decreases in active ERK-1/2 or Akt respectively, when compared with control cells
incubated for 30 min with DMSO (U0126 = 32 ± 5% of control; n = 3; SH-5 = 28 ± 3% of control;
n = 3). As shown in Figure 17, U0126 significantly reduced the production of TNF-α, IL-6 and
nitrite induced by LPS-stimulated microglial cells. Similarly, the inhibition of the Akt pathway, by
SH-5 (1 μM), resulted in a significant reduction of TNF-α, IL-6 and nitrite levels (Figure 17).
However, while LPS-induced expression of IL-1β was significantly reduced by addition of SH-5,
IL-1β expression was not affected by U0126 in LPS-treated microglia (Figure 17). These results
suggest that ERK and Akt could mediate the enhancing effects of LPS on TNF-α, IL-6 and nitrite
induction. In contrast, while the Akt pathway was involved in LPS-induced IL-1β production, the
ERK pathway was not implicated.
CB2 and µ-opioid receptor gene silencing in microglial cells
To confirm the apparent role of CB2 receptors and to investigate the involvement of μ-opioid
receptors, we reduced CB2 and µ-opioid receptor expression in primary microglial cells by siRNA
transfection, in order to cause transient knockdown of the CB2 and μ-opioid receptor genes. Primary
microglial cells were transfected with non-specific random control ribonucleotides  (siRNA
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scramble, siRNActr) or with small interfering RNAs that target CB2 or μ-opioid receptor mRNAs
(siRNACB2 or siRNAμ, respectively) for degradation.
As shown in Figure 18, CB2 and µ-opioid receptor protein expression were strongly reduced after 48
and 72 h of treatment with siRNACB2 and siRNAμ respectively. Therefore, 48 h after siRNACB2 or
siRNAμ transfection, primary microglial cells were treated with either LPS (1 μg·mL-1), JWH-015
(100 nM) or morphine (100 nM), alone and in combination, for 30 min, after which ERK1/2- and
Akt-phosphorylated protein levels were measured. This revealed that inhibition of CB2 receptor
expression was sufficient to block the JWH-015 induced inhibition of ERK1/2 and Akt
phosphorylation levels, increased by morphine in LPS-treated microglia (Figure 19). Furthermore,
inhibition of the expression of µ-opioid receptors blocked morphine-induced increases in pERK1/2
and pAkt in microglia (Figure 19). These results  clearly show the connection between CB2 receptor
stimulation, morphine, ERKs and Akt signalling in activated primary microglial cells.
We also measured cytokine and nitrite levels in microglial cells in which CB2 or μ-opioid receptors
were down-regulated. We found that, in microglial cells with μ-opioid receptors down-regulated,
morphine did not significantly increase IL-1β, TNF-α, IL-6 and nitrite protein levels when
compared to LPS. Similarly, the CB2 agonist JWH-015 did not significantly reduce cytokine and




The presence of opioid receptors on glia and the ability of morphine to prime microglia for
enhanced production of proinflammatory cytokines supports a possible direct interaction of
morphine with glial cells (Chao et al., 1994). As microglial differentiation and immune function is
regulated by activation of CB2 receptors (Stella, 2010), we set out to characterize the signalling
pathways modulated by both μ-opioid and CB2 receptors expressed in microglial cells. CB2 and µ-
opioid receptor ligands (agonist and antagonist) and CB2- and µ-opioid receptor-knockout
microglial cells were used to determine the role of the CB and opioid system in primary microglial
cells. We have described the mechanisms by which CB2 and opioid receptors modulate the MAPK
signal response to LPS, an agent widely used experimentally to create inflammation in the brain
(Lehnardt et al., 2002).
In this study, we demonstrated that (1) morphine enhanced the release of NO and the
proinflammatory cytokines, IL-1β, IL-6, TNF-α, from activated microglial cells; (2) CB2 receptor
stimulation attenuated morphine-induced microglial proinflammatory mediator increases; (3)
morphine-induced microglial proinflammatory mediator increases were μ-opioid receptor
dependent; and (4) CB2 receptor stimulation interfered with morphine action by acting on Akt-
ERK1/2 signalling. Together, these results suggest that CB2 receptors are critical to the activity of
microglia, opposing the morphine-induced release of NO and cytokines from microglial cells.
Therefore, we suggest a novel interaction between µ-opioid- and CB2-receptor systems in microglia,
which is likely to be mediated via the Akt/ERK1/2 pathways.
The influence of CB2 receptor stimulation on µ-opioid receptor-induced cytokine and nitrite
production in primary microglial cells was studied using JWH-015, a CB receptor agonist known to
bind more readily to CB2 than CB1 receptors (Merighi et al., 2010). However, JWH-015 also
stimulates GPR55 (Lauckner et al., 2008). Similarly, different studies have demonstrated that the
CB1 receptor antagonist AM 251 induces GPR55 activity (Lauckner et al., 2008; Henstridge et al.,
2010; Anavi-Goffer et al., 2012). Therefore, even if the activity of CB receptor ligands at GPR55 is
influenced by the assay used to assess receptor-mediated downstream signaling (Henstridge et al.,
2010), a role for GPR55 activation needs to be considered in further pharmacological studies of
cannabinoid actions. Furthermore, a non-selective CB agonist enhanced morphine antinociception
via the CB1 receptor, pointing to the involvement of CB1 receptors in cannabinoid antinociception
produced by CB receptor ligands (Wilson et al., 2008).
56
The first report linking glia to morphine tolerance demonstrated that chronic systemic morphine
increased glia activation in the spinal cord (Song and Zhao, 2001). Other authors have also shown
that chronic morphine administration activated astroglia and microglia (Raghavendra et al., 2002;
Cui et al., 2006). Activated microglial cells in the spinal cord may release proinflammatory
cytokines and other substances thought to facilitate pain transmission (Watkins et al., 2001; 2003).
Therefore, pharmacological attenuation of glial activation represents a novel approach for
controlling neuropathic pain (Watkins et al., 2005). Neuropathic hyperalgesia could lead to lowered
morphine efficacy and quicker development of morphine tolerance (Mayer et al., 1999), and some
authors have suggested that uncontrolled activation of microglial cells after nerve injury can lead to
altered activities of opioid systems or opioid specific signalling (Watkins et al., 2005; 2007). It is
already known that microglia release neuroexcitatory substances in response to morphine, thereby
opposing its effects (Watkins et al., 2001; 2005; 2007). This raises an older hypothesis that
suppression of glial activation and the resulting blockade of proinflammatory cytokine synthesis can
improve morphine efficacy (Song and Zhao, 2001; Raghavendra et al., 2002; Watkins et al., 2007).
The mechanism underlying the involvement of glial cells in morphine tolerance is unclear. It is
possible that morphine can act directly on glial cells, triggering alterations in their morphology and
functions (Raghavendra et al., 2002; 2004). Additionally, glial cells are also considered to be crucial
sources of NO, cytokines and cyclooxygenase products that influence synaptic transmission in the
CNS. Inhibition of these factors may delay morphine tolerance (Powell et al., 1999).
Many current studies aim to find substances inhibiting the biosynthesis of proinflammatory
cytokines. Propentofylline, minocycline and ibudilast inhibit cytokines and decrease astroglia and
microglia activation, thereby suppressing the development of neuropathic pain (Romero-Sandoval
et al., 2008). The beneficial effects of minocycline are associated with a reduction of inducible NO
synthase and cyclooxygenase-2 expression and a decrease in cytokine and prostaglandin release in
microglia (Yrjanheikki et al., 1998; 1999). Further studies have shown that minocycline reduced
microglial activation by inhibiting p38 MAPK in microglia and, in this way, delayed morphine
tolerance (Romero-Sandoval et al., 2008). Ibudilast may counteract opioid tolerance by blocking the
activation of glial cells in the spinal cord in rodents (Romero-Sandoval et al., 2008). In the present
work, we found that in activated microglial cells, morphine increased Akt and ERK kinase
phosphorylation. ERK1/2 kinases are known to regulate the production of proinflammatory
mediators from glial cells (Watkins et al., 2001). Furthermore, p38 and ERK kinases have been
implicated in the development of morphine-induced hyperalgesia and antinociceptive tolerance
(Cuiet al., 2006; Wang et al., 2009). Therefore, it is of interest that CB2 receptor stimulation was
able to downregulate Akt and ERK1/2 activation induced by morphine in activated microglial cells.
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Our data indicate that the CB2 receptor did not mediate its effects through p38 and JNK1/2 kinases.
However, β-caryophyllene, a CB2 receptor selective agonist, modulates JNK1/2 in LPS-stimulated
monocytes (Gertsch et al., 2008). As microglia are considered as the resident macrophage-like cells
in the brain, we suggest that this contrasting behavior may be due to the different experimental
conditions, for example, time of ligand incubation (30 min vs. 3 h for microglia and monocytes
respectively) or LPS concentration (1 µg·mL-1 vs. 0.313 µg·mL-1 for microglia and monocytes
respectively). As for ERK1/2 signalling, it has been previously observed that CB2 receptor
stimulation leads to ERK-mediated cellular activation and anti-inflammatory effects in
monocytes/macrophages and microglia (Gertsch et al., 2008; Correa et al., 2010). Similarly, a more
recent study has demonstrated that CB2 receptor stimulation in microglial cells induced an anti-
inflammatory phenotype and reduced migration via MKP-induced ERK dephosphorylation
(Romero-Sandoval et al., 2009). Agonist at CB receptors inhibited the production of
proinflammatory molecules, which were induced by LPS, in CNS glial cells (Molina Holgado et al.,
2002; Fachinetti et al., 2003; Ortega-Gutiérrez et al., 2005; Sheng et al., 2005; Correa et al., 2008;
2009). In particular, CB2 receptors influence the production of the potent inflammatory mediator
NO, released from quiescent, and, to a greater extent, from activated microglia (Stella, 2010). In
this work, we have described the activation of the ERK1/2 and Akt pathways by LPS leading to an
increment in TNF-α, IL-6 and nitrite production. In contrast, while Akt is engaged as the signalling
pathway generating IL-1β in LPS-activated microglia, the ERK pathway was not implicated. The
involvement of the ERK-MAPK pathway in IL-1β production by LPS is controversial. Some
reports show that the ERK cascade is important for LPS-stimulated production of IL-1β in
macrophage cell lines and monocytes (Scherle et al., 1998; Caivano and Cohen, 2000). However, it
has also been reported that the ERK pathway is not essential for IL-1β production in BV-2
microglia (Watters et al., 2002). Consistent with findings on BV-2 microglia cell lines, our study
indicates that the regulation of LPS-stimulated IL-1β production is ERK-independent also in
primary microglia.
According to previous studies showing that CB2 receptor mRNA and protein are modulated in vitro
differentially in relation to cell activation state (Carlisle et al., 2002; Cabral et al., 2008), we have
demonstrated that LPS increases CB2 receptor expression level in primary microglial cells. It is
important to mention that CB2 receptors, identified in the healthy brain, mainly in glial elements,
and, to a lesser extent, in certain subpopulations of neurons, are dramatically up-regulated in
response to damaging stimuli, which supports the idea that the cannabinoid system behaves as an
endogenous neuroprotective system. This CB2 receptor up-regulation has been found in many
neurodegenerative disorders, which supports the beneficial effects found for CB2 receptor agonists
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in these pathologies (Fernández-Ruiz et al., 2011). Now, we have characterized, for the first time,
the events occurring in LPS-activated microglia via CB2 receptor stimulation, which reduces not
only ERK1/2- but also Akt-phosphorylation increases induced by LPS. Therefore, CB2 receptors
expressed in microglia may participate in regulating neuroinflammation and provide
neuroprotection by tempering morphine-induced cytokine and NO synthesis through ERK1/2 and
Akt signalling in activated microglia. Interestingly, in microglia, we showed that the effects of
morphine were mediated by the µ-opioid receptor subtype. This accords with previous observations
describing the involvement of endocannabinoids in the peripheral antinociception induced by the µ-
opioid receptor agonist morphine. In contrast, the release of endocannabinoids appears not to be
involved in the peripheral antinociceptive effect induced by κ- and δ-opioid receptor agonists (da
Fonseca Pacheco et al., 2008). At the same time, it would be possible that certain effects of CB2
receptor agonists in different models for inflammation and possibly their analgesic effects
previously reported, actually reflect their interaction with endogenous opioids. In particular, it has
been demonstrated that morphine is present in human gliomas (Olsen et al., 2005) and that it
increases the proliferation of human glioblastoma cells (Lazarczyk et al., 2010). Because morphine
is used to alleviate pain associated with cancers, this study suggests that a combination of CB 2
receptor agonists to prevent morphine-induced proliferation may have clinically important
implications.
In conclusion, the novel finding of this study is the existence of a receptor–receptor interaction
when the receptors are co-expressed in the same cells leading to the interaction of their intracellular
pathways. In particular, CB2 receptor stimulation counteracts the ability of morphine to upregulate
Akt and ERK1/2 activation induced by LPS, thus reducing NO and proinflammatory cytokine
release, a process which is ERK- and Akt-dependent. The studies presented here are the first to
assess the signalling mechanisms through which CB2 receptor stimulation modulates morphine
effects on microglia and MAPK activation. The ability to modulate microglia and MAPK is very
interesting because their activation in the central and peripheral nervous system contributes to
morphine tolerance and dependence (Mayer et al., 1999; Watkins et al., 2001; Raghavendra et al.,
2002; 2004; Galeotti et al., 2006; Cunha et al., 2010). Our results indicate a regulatory role for CB 2
receptors in preventing excessive microglial cell response to injury in activated microglia. Based on
the findings obtained in the present study, we will advance our research to reinforce the idea that the
cannabinoid system exerts an important control on the tolerance and dependence effects induced by
opioids. In particular, it will be interesting to evaluate the impact of low-dose combinations of
cannabinoids and opioids to effectively treat acute and chronic pain, especially pain that may be
resistant to opioids alone. It is well known that the use of cannabinoids, like that of the opioids, has
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liability for abuse potential. The use of marijuana as a therapeutic pain management tool has
generated a great deal of publicity and controversy. However, it should be noted that CB2 receptor
agonists, in comparison with CB1 agonists, lack the undesirable CNS side effects, like sedation and
psychotomimetic effects (Fernández-Ruiz et al., 2011; Dhopeshwarkar et al, 2014). Therefore, the
development of selective CB2 receptor agonists might open new avenues of therapeutic intervention
to reduce the release of proinflammatory mediators especially during morphine therapy.




Figure 11: Detection of CB2 and µ-opioid receptors in primary microglial cells. (A), Cell surface
expression of CD11b and intracellular expression of GFAP by flow cytometry analysis. Primary
microglial cells were treated with specific monoclonal antibodies (black histograms) or with
isotype-matched irrelevant monoclonal antibodies (empty histograms, controls). (B), CB2 and µ-
opioid receptor detection by Western blot assay in quiescent and LPS-activated (1 μg·mL-1 for 30
min) primary microglial cells. Tubulin shows equal loading of protein. The expression of CB2
receptors in CHO-hCB2 cells and of μ-opioid receptors in mouse brain extracts, used as positive
controls (Control), is shown. (C), CB2 receptor detection by Western blot assay in quiescent and
LPS-activated (1 µg·mL-1 for 6, 12 and 24 h) primary microglial cells. Tubulin shows equal loading
of protein.
Figure 12: Effect of opioid receptor ligands on LPS-induced production of proinflammatory
cytokines and nitrite in primary microglial cells. Microglial cells were treated with either LPS
alone, LPS + morphine 100 nM (MOR), LPS + naloxone, a non-selective opioid receptor antagonist
(Nal; 100 nM), LPS + DAMGO, a selective µ-opioid receptor agonist (100 nM), LPS + DPDPE, a
selective δ-opioid receptor agonist (100 nM), LPS + U69593, a selective κ-opioid receptor agonist
(100 nM) or LPS + CTAP, a selective µ-opioid receptor antagonist (100 nM) for 24 h. The
antagonists were added 30 min before morphine. Data shown are mean ± SEM values of four
separate experiments performed in triplicate (n = 4). *P < 0.01 significantly different from control
conditions (absence of drugs, CTR); #P < 0.01 significantly different from LPS conditions (0); §P <
0.01 significantly different from LPS + MOR; †P < 0.01 significantly different from LPS +
DAMGO; analysis was by ANOVA followed by Dunnett’s test.
Figure 13: Effect of opioid and CB receptor ligands on LPS-induced production of
proinflammatory cytokine and nitrite in primary microglial cells. Microglial cells were treated with
either LPS alone, LPS + morphine (MOR; 100 nM), LPS + JWH-015 a CB 2 receptor agonist (JWH;
100 nM), LPS + DAMGO (100 nM), LPS + AM 251 a selective CB1 receptor antagonist (100 nM)
or LPS + AM 630 a selective CB2 receptor antagonist (100 nM) for 24 h. The antagonists were
added 30 min before morphine. Data shown are mean ± SE values of four separate experiments
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performed in triplicate (n = 4). *P < 0.01 significantly different from control conditions (absence of
drugs, CTR); #P < 0.01 significantly different from LPS conditions (0); §P < 0.01 significantly
different from LPS + MOR; †P < 0.01 significantly different from LPS + MOR + JWH; analysis
was by ANOVA followed by Dunnett’s test.
Figure 14: Morphine-enhanced Akt and ERK1/2 phosphorylation in a µ-opioid receptor-dependent
manner. (A), Western blot analysis of Akt, ERK1/2, p38, and JNK1/2 phosphorylation in primary
microglial cells incubated for 30 min with morphine (MOR) (1–1000 nM). The immunoblot signals
were quantified using a VersaDoc Imaging System (Bio-Rad). The ratio of phospho-protein to total
protein is used. The mean values of four independent experiments (one of which is shown) were
normalized to the result obtained with morphine-untreated cell cultures (0). Densitometric analysis
is shown. The unstimulated control (0, cells in the absence of morphine) was set to 100%. Data
shown are mean ± SE values of four separate experiments performed in triplicate (n = 4). *P < 0.05
significantly different from unstimulated control; analysis was by ANOVA followed by Dunnett’s
test. (B), Primary microglial cells were treated with morphine (100 nM) for 0, 15, 30 and 60 min,
subjected to Western blot analysis and probed with anti-pERK1/2, anti-pAkt, then Akt and ERK1/2
antibody. The ratio of phospho-protein to total protein is used. Data shown are mean ± SE values of
four separate experiments performed in triplicate (n = 4). *P < 0.01 significantly different from
control conditions (0); #P < 0.01 significantly different from LPS conditions; analysis was by
ANOVA followed by Dunnett’s test. (C), Image of Western blot membrane probed with anti-
pERK1/2, anti-pAkt, then Akt and ERK1/2 antibody of primary microglial cells pre-treated for 30
min with 0 or 100 nM of the µ-opioid receptor antagonist CTAP, then treated for 30 min with 0 or
100 nM morphine. The ratio of phospho-protein to total protein is used. Data shown are mean ±
SEM values of four separate experiments performed in triplicate (n = 4). *P < 0.01 significantly
different from untreated cells; analysis was by ANOVA followed by Dunnett’s test.
Figure 15: Effect of CB2 receptor stimulation in morphine-treated activated primary microglial
cells. JWH-015 and morphine (MOR) effect on Akt, ERK1/2, p38 and JNK1/2 phosphorylation in
primary microglial cells treated with LPS. Microglial cells were incubated with DMSO vehicle
(CTR), with MOR (100 nM), or with JWH-015 (100 nM) alone and in combination in the presence
of LPS 1 μg·mL- 1 for 30 min. The mean values of four independent experiments (one of which is
shown) were normalized to the result obtained in cells in the absence of LPS (CTR). Data shown
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are mean ± SEM values of four separate experiments performed in triplicate (n = 4). CTR was set to
100%. The immunoblot signals were quantified using a VersaDoc Imaging System (Bio-Rad).
Densitometric analysis of kinase activation is shown. The ratio of phospho-protein to total protein is
used. *P < 0.05 significantly different from CTR; #P < 0.05 significantly different from cells treated
with LPS; §P < 0.05 significantly different from cells treated with LPS + morphine; analysis was by
ANOVA followed by Dunnett’s test.
Figure 16: Effect of CB and opioid receptor blockade in morphine-treated activated primary
microglial cells. Primary microglial cells were incubated with either DMSO vehicle (lane 1),
morphine (MOR; 100 nM), naloxone a non-selective opioid receptor antagonist (Nal; 100 nM),
JWH-015 100 nM, AM 251 a selective CB1 receptor antagonist (100 nM) or AM 630 a selective
CB2 receptor antagonist (100 nM) in the presence of LPS (1μg·mL-1) for 30 min. The mean values
of four independent experiments (one of which is shown) were normalized to the result obtained in
cells in the absence of LPS (lane 1). Data shown are mean ± SEM values of four separate
experiments performed in triplicate (n = 4). The unstimulated control (lane 1) was set to 100%. The
immunoblot signals were quantified using a VersaDoc Imaging System (Bio-Rad). Densitometric
analysis of kinase activation is shown. The ratio of phospho-protein to total protein is used. *P <
0.05 significantly different from untreated cells (lane 1); #P < 0.05 significantly different from cells
treated with LPS (lane 2); §P < 0.05 significantly different from cells treated with LPS + morphine
(lane 5); †P < 0.05 significantly different from LPS + morphine + JWH-015 (lane 6); analysis was
by ANOVA followed by Dunnett’s test.
Figure 17: Effect of kinase inhibitors on LPS-induced production of proinflammatory cytokines
and nitrite in primary microglial cells. Microglial cells were treated with LPS with either the MEK-
1/2 inhibitor U0126 (1 μM) or the Akt inhibitor SH-5 (1 μM) for 24 h. The inhibitors were added 30
min before LPS. Data shown are mean ± SEM values of four separate experiments performed in
triplicate (n = 4); *P < 0.01 significantly different from control conditions (CTR); #P < 0.01
significantly different from LPS conditions; analysis was by ANOVA followed by Dunnett’s test.
Figure 18: CB2 and µ-opioid receptor expression silencing. (A), Primary microglial cells were
treated with either scrambled (-) (siRNAcontrol), with siRNACB2 (+) or with siRNAμ and cultured for
24, 48 and 72 h. Tubulin shows equal loading of protein. Densitometric quantification of CB2 and
µ-opioid receptor by Western blot is shown; the immunoblot signals were quantified using a
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VersaDoc Imaging System (Bio-Rad). Plots are mean ± SEM values of four separate experiments
performed in triplicate (n = 4); *P < 0.01 significantly different from control (scrambled siRNA
transfected cells); analysis was by ANOVA followed by Dunnett’s test.
Figure 19: Primary microglial cells were treated with either siRNActr, siRNACB2 or siRNAμ for 48 h
and cultured with LPS (1 μg·mL-1) alone or plus morphine (MOR; 100 nM), JWH-015 (JWH; 100
nM) alone and in combination for 30 min. Densitometric analysis of phosphorylated isoform is
shown. The ratio of phospho-protein to total protein is used. The immunoblot signals were
quantified using a VersaDoc Imaging System (Bio-Rad). The mean values of four independent
experiments (one of which is shown) were normalized to the result obtained in cells in the absence
of LPS. The unstimulated control was set to 100%. *P < 0.05 significantly different from
unstimulated control (CTR); #P < 0.05 significantly different from cells treated with LPS; §P < 0.05
significantly different from LPS + MOR; analysis was by ANOVA followed by Dunnett’s test.
Figure 20: Primary microglial cells were treated with either siRNActr, siRNACB2 or with siRNAμ for
48 h and cultured with LPS (1 μg·mL-1) alone or plus morphine (MOR; 100 nM) or JWH-015
(JWH; 100 nM) alone and in combination for 24 h. The unstimulated control (CTR) was set to
100%. Data shown are mean ± SEM values of four separate experiments performed in triplicate (n
= 4); *P < 0.05 significantly different from CTR; #P < 0.05 significantly different from LPS; §P <
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Morphine mediates a proinflammatory phenotype via µ-




Opioids are potent analgesics and are irreplaceable for the treatment of severe pain and in
anesthesia. They mediate their effects via three receptors termed μ-, δ- and κ-opioid receptors.
Among these, μ-opioid receptors play an outstanding role, because they mediate effects of
morphine and most clinically used opioids (Frolich et al., 2011; Kieffer et al.,2009). However,
marked reduction in the analgesic properties of opiates resulting from repeated use significantly
hinders the prolonged clinical use of these drugs. Although the exact mechanisms of opiate
tolerance remain unknown, it has been suggested that the activation of microglia in response to
morphine and the consequent production of pro-inflammatory cytokines plays a key pathogenic
role. For this reason, many current studies aim to find substances inhibiting the biosynthesis of pro-
inflammatory cytokines.
Recently, we have demonstrated that morphine and the μ-opioid receptor agonist DAMGO induce
the activation of Akt and ERKs in microglial cells. In addition, μ-opioid receptors increase NO and
pro-inflammatory cytokine secretion, e.g. IL-1β, TNF-α and IL-6, through Akt and ERK signalling
(Merighi et al., 2012b). However, the mechanisms that occur in the GPCR signalling by which μ-
opioid receptors signal to ERKs have not been studied in detail.
Microglia, brain inflammatory cells, are activated in injured brain where they release inflammatory
mediators such as nitric oxide (NO), tumor necrosis factor-alpha (TNF-α), and prostaglandins
(Minghetti et al., 1995; Lee et al., 1993; Chao et al., 1992; Grace et al., 2014). The inflammatory
mediators could protect tissues from bacterial infection but also could potentiate the damage of
neurons (Minghetti et al., 1998). Activated microglial cells in the spinal cord may release
proinflammatory cytokines and other substances thought to facilitate pain transmission (Watkins et
al., 2003; 2001). Therefore, pharmacological attenuation of glial activation represents a novel
approach for controlling pain (Ock et al., 2010; Watkins et al., 2005). Although the intracellular
signalling molecules involved in microglial activation have not been fully understood, protein
kinase C (PKC) has been considered as an important mediator of microglial activation. In particular,
it has been reported that PKC inhibitors reduced NO release from lipopolysaccharide (LPS)-treated
microglia (Nakai et al., 1998; Yoon et al., 1994).
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Protein kinase Cε
Among different effectors, PKC has attracted a great deal of attention because of its prominent role
in synaptic plasticity and memory. PKC is an integral component of most GPCR signaling
pathways to ERK/MAPK (Belcheva et al., 2005). Accordingly, PKC was found to be an early
signalling component in the opioid pathway to ERK (Zheng et al., 2008; Bohn et al., 2000; Fukuda
et al., 1996). Nevertheless, little is known about the actual isoforms involved in this pathway. 
PKC is a multi-gene family with at least 10 members that differ in their tissue expression,
subcellular localization, activator and cofactor requirements, and substrate specificity. PKC
serine/threonine kinases require diacylclycerol (DAG) and phosphatidyl serine (PS) for their
activation, while according to their dependency on Ca2+ are classified into conventional, Ca2+-
dependent cPKCs α, β, and γ, and into novel, Ca2+-independent nPKCs δ, ε, η, θ; the newest and
atypical PKCs, aPKC ζ and λ/ι require only PS (Freeley et al., 2011; Steinberg et al., 2008). PKC
isoforms are regulated by their phosphorylation and translocation; once phosphorylated, PKC
isoforms are rendered catalytically competent and are activated upon their translocation to cell
membrane. Therefore, activation of PKC isoforms is assessed by their phosphorylation and
membrane translocation (Sudan et al., 2012). Most PKC isoforms are widely expressed in the brain
with higher concentrations in the cerebral structures and areas known to participate in memory
processes. PKCε in particular, a prominent PKC in differentiating and differentiated neurons
(Mangoura et al., 2006; Prekeris et al., 1996), is considered critical in learning and memory, and in
synaptic remodeling (Hama et al., 2004). There is evidence that PKCε isoform is activated by
opiates, raising the possibility that PKCε modulates behavioral responses to opiates. The
interactions between the transition from acute to chronic pain and the development of opioid
tolerance and dependence are mediated by PKCε (Joseph et al., 2010). Recently, it has been
demonstrated that morphine uses the PKCε pathway to induce ERK phosphorylation and receptor
desensitization (Zheng et al., 2011). Furthermore, PKC inhibitors can reduce morphine anti-
nociceptive tolerance (Smith et al., 2007). Mice that lack PKCε isozyme (PKCε -/-) show enhanced
responses to morphine (Newton et al., 2007) and increased analgesia and thermal behavioral
tolerance to specific cannabinoid agonists (Wallace et al., 2009). Several aspects of the immune
system in these animals were normal although macrophages were defective in the production of
LPS-stimulated TNF-α, IL-1β, PGE2, and NO. There were also deficits in LPS-stimulated MAPK
and NFkB activation (Castrillo et al., 2001). 
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Therefore, the present study was designed to identify in detail the receptor-proximal signalling
events that link μ-opioid receptors to activation of Akt and ERKs in microglial cells and to define
the molecular mechanism contributing to the ability of morphine to increase inflammatory
mediators such as NO, TNF-α, IL-1β and IL-6 in activated microglial cells. In particular, the role of




One-day-old Balb/c mice were obtained from Charles River (Calco, Italy). Animal care procedures
conformed to the guidelines issued by the European Council (86/609/EEC) were approved by the
local Animal Care and Ethics Committee.
Reagents and antibodies
Tissue culture media and growth supplements were obtained from Lonza (Euroclone, Milan, Italy).
U0126 (MEK-1 and MEK-2 inhibitor, soluble in DMSO) was provided by Promega (Milan, Italy).
Phosphorylated p44/42 MAPK (ERK1/2) (Thr 202/Tyr 2204) (cat. #4370) and total anti-ERK1/2 pAb,
anti-COX-2 (cat. #4842), anti-iNOS (cat. #2977), phosphorylated (Ser 473) (cat. #9271) and total
Akt were from Cell Signaling Technology (Euroclone, Milan, Italy). SH5 (inhibitor of Akt) was
from Enzo Life Sciences (Vinci-Biochem, Vinci, Florence, Italy). Anti-PKCε (cat. #06-991) used in
Western blot assay was from Millipore (Milan, Italy). Anti-PKCε (cat. #NBP1-30126) used in
immunofluorescence assay was from Novus Biological (DBA, Milan, Italy). Phosphorylated (Ser
729) (sc-12355) PKCε antibody, small interfering RNA (siRNA) PKCε (sc-36250) and MOR-1
siRNA (sc-35958) were from Santa Cruz Biotechnology (DBA, Milan, Italy). RNAiFectTM
Transfection Kit was from Qiagen (Milan, Italy). Unless otherwise stated, all other chemicals were
purchased from Sigma (Milan, Italy). Drug and molecular target nomenclature conforms to
Alexander et al., 2013.
Primary microglial cell cultures
Primary glial cultures were prepared as described in a previous study (Merighi et al., 2012a).
Briefly, after anesthesia (Zoletil 100, 30 mg·kg-1, Virbac Laboratories, France) and decapitation,
forebrains from newborn Balb/c mice were excised, meninges removed, and tissue dissociated
mechanically. Cells were re-suspended in Dulbecco’s modified Eagle medium (DMEM/F12)
supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin,
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then plated on poly-D-lysine-coated (5 μg·mL-1) 75 cm2 flasks (Falcon; Euroclone, Milan, Italy).
After 15 days, the flasks were shaken vigorously to remove loosely adherent microglia. The
supernatant was plated on multi-well culture plates for 2 h, and the medium was changed to remove
nonadherent cells. Cells were grown in a humidified environment containing 5% CO2 at a constant
temperature of 37°C. The purity of microglial cultures was assessed by examining cell morphology
under phase-contrast microscopy, and was confirmed by flow cytometry with Mac-1 anti-CD11b
antibody (BD Pharmingen, Milan, Italy).
Cell cultures
Cells were maintained in DMEM/F12 medium containing 10% FBS, penicillin (100 U·mL-1),
streptomycin (100 μg·mL-1) at 37°C in 5% CO2/95% air. Cells were split 2 or 3 times weekly at a
ratio between 1:5 and 1:10.
Flow cytometry of primary microglial cells
Aliquots of 0.5 x 106 cells were incubated for 40 min at 4°C with either specific Phycoerythrin
(PE)-labeled antibodies, or isotype-matched irrelevant IgG-PE (Beckman Coulter) as negative
control. Cells were washed with PBS and characterized for CD11b and GFAP expression by flow
cytometry with PE-labeled anti-CD11b MoAb (BD Pharmingen, Milan, Italy) and the fluorescein
isothiocyanate (FITC)-labeled anti-GFAP MoAb (BD Pharmingen, Milan, Italy). In particular,
GFAP immunophenotyping was performed in permeabilized cells, using IntraPrepTM
fixing/permeabilization reagent (Beckman Coulter) (Gobbi et al., 2003). Analysis was performed on
an Epics XL flow cytometer (Beckman Coulter, Fullerton, CA) using Expo ADC software
(Beckman Coulter).
Primary microglial cell exposure to opioids and LPS treatment
LPS, a cell wall component of Gram-negative bacteria, is a potent activator of glia. Hence,
microglial cells were treated with 1 µg·mL-1 LPS (from Escherichia coli, serotype 055:B5) (soluble
in cell culture medium) before commencing incubation with opioid ligands. Unless otherwise
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stated, the concentration of morphine, naloxone, DAMGO, DPDE, U69593 and CTAP was 100 nM,
which is the ligand concentration able to occupy 99% of the receptors at equilibrium. Microglia
were then maintained in DMEM/F12 containing opioids or their vehicle, and harvested after
treatment at the indicated times.
PKCε activity
PKCε activity has been modulated by εV1-2 (CEAVSLKPT) peptide conjugated by a cysteine
disulfide bound to TAT47–57 (CYGRKKRRQRRR) (Brandman et al., 2007), generously donated
by Prof. P. Mirandola, University of Parma, Italy. Briefly, εV1-2 is a specific PKCε inhibitor
designed from C2 region of PKCε protein that acts as a competitor of binding between PKCε and its
anchoring protein εRACK. Microglial cells were treated with 1 μM of εV1-2.
Nitrite assay for primary microglial cells
NO synthase activity was assessed indirectly by measuring nitrite (NO2-) accumulation in the cell
culture media using a colorimetric kit (Calbiochem, Milan, Italy). At the end of the treatment
period, the nitrite concentration in the conditioned media was determined according to a modified
Griess method (Merighi et al., 2012a). Briefly, the NADH-dependent enzyme nitrate reductase was
used to convert the nitrate to nitrite prior to quantification of the absorbance, measured at 540 nm
by a spectrophotometric microplate reader (Fluoroskan Ascent, Labsystems, Sweden). Values were
obtained by comparison with reference concentrations of sodium nitrite.
Enzyme-linked immunosorbent assay (ELISA)
The levels of IL-1β, TNF-α and IL-6 protein secreted by the cells in the medium were determined
by ELISA kits (R&D Systems). In brief, subconfluent cells were changed into fresh medium in the
presence of solvent or various concentrations of drugs. The medium was collected, and IL-1β, TNF-
α and IL-6 protein concentrations were measured by ELISA according to the manufacturer’s
instructions. The results were normalized to the number of cells per plate. The data were presented
as mean ± S.E. from four independent experiments performed in triplicate.
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Western blotting for primary microglial cells
Western blot assay was performed as previously described (Merighi et al., 2009; 2006). Aliquots of
total protein sample (50 μg) were analyzed using antibodies specific for phosphorylated or total
p44/p42 MAPK (1:1000 dilution), phosphorylated (1:200) or total (1:1000) PKCε, phosphorylated
or total Akt (1:1000 dilution), for µ-opioid receptors. Specific reactions were revealed with
Enhanced Chemiluminescence Western blotting detection reagent (Amersham Corp., Arlington
Heights, IL). The membranes were then stripped and re-probed with tubulin (1:250) to ensure equal
protein loading.
Densitometry analysis
The intensity of each immunoblot assay band was quantified using a VersaDoc Imaging System
(Bio-Rad, Milan, Italy). Mean densitometric data from independent experiments was normalized to
the results obtained with control cell cultures. The ratio of phospho-protein to total protein was
reported in a densitometric analysis.
Treatment of primary microglial cells with siRNA
Microglial cells were plated in six-well plates and grown to 50–70% confluence before transfection.
Transfection of siRNAPKCε or siRNAμ was performed at a concentration of 100 nM using
RNAiFectTM Transfection Kit (Qiagen, Milan, Italy). Cells were cultured in complete media and
total proteins were isolated at 24, 48 and 72 h for Western blot analysis of PKCε and µ-opioid
receptor protein. A randomly chosen non-specific siRNA was used under identical conditions as
control (Merighi et al., 2007; 2005).
Immunofluorescence
Microglial cells were seeded on glass coverslips in 6-well plates overnight at 37°C in a humidified
atmosphere containing 5% CO2. Microglial cells were treated with 1 µg·mL-1 LPS alone or in
combination with morphine 100 nM. After 10 min the medium was removed, cells were washed
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twice with PBS, mixed in 4% paraformaldehyde for 10 min, permeabilized in a PBS solution
containing 0.2% Triton X-100, 1% BSA and incubated for 1 h with PBS-plus 10% goat serum.
Cells were then stained (for 90 min at room temperature) with a 1:200 dilution of an anti-PKCε
antibody (Novus Biological) in PBS-plus 1% goat serum. The coverslips were rinsed three times
and then the cells were labeled with a FITC-conjugated secondary antibody in PBS for 1 h.
Coverslips were stained with 4',6'-diamino-2-phenyl-indole (DAPI), mounted in DABCO glycerol-
PBS, and observed on a Nikon fluorescent microscope.
Statistical analysis
All data are reported as mean ± S.E. of independent experiments and are indicated in the figure
legends. Each experiment was performed by using the microglial cells derived from one single
mouse, and was performed in triplicate. The experiments were repeated at least four times as
indicated from n-values that represent the number of mice used. Data sets were examined by
analysis of variance (ANOVA) for comparisons between multiple groups and Dunnett’s test for




Morphine alters the LPS-induced expression and activation of PKCε
Expression of the myeloid cell surface antigen CD11b was analyzed in primary microglial cells by
flow cytometry. Cells were treated with specific MoAbs or isotype-matched irrelevant MoAbs.
Microglia were negative for the astrocyte-specific protein GFAP but showed significant positive
staining for CD11b, as compared to the isotype control, thereby indicating high expression levels of
the microglial cell marker CD11b (data not shown).
We have studied by immunofluorescence the involvement of PKCε in microglial cells treated with
morphine. PKCε protein expression in quiescent microglia was localized to nuclear compartment
(Figure 21) while a faint signal was observed in the cytoplasm. Treatment with morphine (100 nM)
did not change PKCε expression or localization. On the contrary, LPS 1 µg·mL-1 alone or LPS +
morphine 100 nM increased PKCε expression and a clear cell membrane translocation of this
enzyme was also observed. These results were confirmed through the analysis of phosphorylation
levels and membrane translocation of PKCε in microglial cells by Western blotting (Figure 22). In
particular, microglial cells were treated with either LPS 1 µg·mL -1 alone or LPS + morphine 100
nM for 0, 5, 10, 15, 30, or 60 min. The cytosolic and membrane fractions of cells were subsequently
prepared for Western blot analysis of PKCε. In separate experiments, after treatment, whole-cell
lysates were prepared and analyzed by Western blot analysis for phospho-PKCε. The presence of
PKCε was determined in unstimulated microglial cells. We found that LPS induces phosphorylation
of PKCε in a time-dependent manner, as demonstrated using specific phospho-PKCε antibody,
which detects PKCε isoform only when phosphorylated at indicated specific site (Ser-729) (Figure
22A). In the presence of morphine 100 nM, PKCε phosphorylation induced by LPS was
significantly higher than LPS alone, with a maximal activation at 10 min (Figure 22B). Consistent
with PKCε phosphorylation results, incubation of cells with LPS 1 µg·mL-1 alone provoked the
cytosol-to-membrane translocation and thus activation of PKCε (Figure 22C). In the presence of
morphine 100 nM, PKCε translocation was significantly higher than LPS 1 µg·mL-1 alone and was
maximal at 10 min. A decrease in PKCε translocation induced by LPS + morphine was observed at
15 min followed by a further activation at 30 and 60 min (Figure 22D). Furthermore, to confirm that
phosphorylation of PKCε leads to membrane localization, we have shown the presence of
phosphorylated membranous PKCε. In particular, we have performed a Western blot analysis using
specific phospho-PKCε antibody on membrane fractions. We found that PKCε phosphorylation
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induced by LPS + morphine (for 10 min) was significantly higher than LPS alone also in the
membranous fraction (Figure 22E,F).
Effect of opioid receptor ligands on LPS-induced expression and activation of
PKCε
Morphine-induced PKCε activation was found to be opioid receptor-mediated. Pretreatment of cells
with the broad-range opioid receptor antagonist naloxone for 30 min abolished morphine-induced
phosphorylation (Figure 23) of PKCε at 10 min in LPS-activated microglial cells. Furthermore,
DAMGO (100 nM), a µ-opioid receptor selective agonist, mimicked morphine effects on microglial
PKCε activation (Figure 23). Conversely, DPDPE and U-69593, δ- and κ-receptor selective
agonists, respectively, had no effect on LPS-induced PKCε activation (Figure 23). Finally,
pretreatment of microglial cells with CTAP 100 nM, a µ-opioid receptor selective antagonist, before
treatment with DAMGO 100 nM, abolished µ-opioid receptor agonist’s effect on LPS-induced
PKCε activation (Figure 23). These results demonstrate that morphine activates PKCε in mouse
activated microglial cells via the µ-opioid receptor.
µ-opioid receptor gene silencing in microglial cells
To confirm the apparent role of μ-opioid receptors we reduced their expression in primary
microglial cells by siRNA transfection, in order to cause transient knockdown of the µ-opioid
receptor gene. Primary microglial cells were transfected with nonspecific random control
ribonucleotides (siRNA scramble, siRNActr) or with small interfering RNAs that target µ-opioid
receptor mRNA (siRNAμ) for degradation. As shown in Figure 24A, µ-opioid receptor protein
expression was strongly reduced after 48 and 72 h of treatment with siRNAμ. Therefore, 48 h after
siRNAμ transfection, primary microglial cells were treated with either LPS 1 µg·mL -1, or LPS +
morphine 100 nM, for 10 min, after which cytosolic and membrane fractions of cells were
subsequently prepared for Western blot analysis of PKCε. In separate experiments, after treatment,
whole-cell lysates were prepared and analyzed by Western blot analysis for phospho-PKCε. We
found that the inhibition of µ-opioid receptor expression blocks morphine-increases in phospho-
PKCε and PKCε translocation in microglia (Figure 24B). These results clearly show the connection
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between µ-opioid receptor stimulation, morphine, and PKCε signaling in activated primary
microglial cells.
PKCε isoform modulates morphine-induced Akt and ERK1/2 phosphorylation
in activated microglial cells
Because phosphorylation and membrane translocation of PKCε isoform were regulated by
morphine, which also regulates Akt and ERK1/2 phosphorylation (Merighi et al., 2012b), we next
examined whether the selective inhibition of PKCε isoform by its inhibitor εV1-2 and siRNA
regulated morphine-induced signaling through these two kinases in activated microglial cells.
To study the specificity of εV1-2, we treated BALB/c-derived microglial cells with the PKC
inhibitor for 2 h followed by stimulation with LPS and morphine for 10 min and studied PKCε
isoform activation by membrane translocation. We observed that εV1-2 inhibited morphine-induced
translocation of the PKCε isoform for which it was specific (Figure 25). Indeed, to investigate the
possible relationship between PKCε and Akt–ERK1/2 kinases, we examined the activation of Akt
and ERK1/2 by LPS plus morphine in the presence of εV1-2. On the basis of our earlier study,
induction of Akt and ERK1/2 activation by LPS plus morphine was most significant 15 min after
treatment. Therefore, cells were pretreated with εV1-2 for 30 min before LPS plus morphine
stimulation for 15 min. We found that Akt and ERK1/2 phosphorylation at 15 min following LPS
alone or LPS plus morphine treatment is attenuated by the PKCε inhibitor εV1-2 (Figure 25). These
results demonstrate that the inhibition of PKCε isoform activation by its translocation inhibitor
peptide εV1-2 reduced LPS- and morphine-induced Akt and ERK1/2 phosphorylation in activated
microglial cells (Figure 25), indicating that the activation of PKCε occurs upstream of Akt and
ERK1/2 kinases. To confirm the role of PKCε and to investigate the involvement of µ-opioid
receptors in the signalling under investigation, we examined the effect of siRNAPKCε on µ-opioid
receptor-elicited Akt and ERK1/2 phosphorylation. In order to cause transient knockdown of PKCε
gene we reduced PKCε expression in primary microglial cells by siRNA transfection. Primary
microglial cells were transfected with nonspecific random control ribonucleotides (siRNA
scramble, siRNActr) or with small interfering RNAs that target PKCε mRNA (siRNAPKCε) for
degradation. As shown in Figure 26A, PKCε protein expression was strongly reduced after 24 and
48 h of treatment with siRNAPKCε. Therefore, 24 h after siRNAPKCε transfection, primary microglial
cells were treated with either LPS 1 µg·mL-1 alone, LPS + morphine 100 nM, or LPS + DAMGO
100 nM for 15 min, after which ERK1/2- and Akt-phosphorylated protein levels were measured.
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The results revealed that inhibition of PKCε expression is sufficient to block ERK1/2 and Akt
phosphorylation levels increased by morphine in LPS-treated microglia (Figure 26B). Furthermore,
to analyze iNOS protein expression, primary microglial cells were stimulated with LPS in the
absence or presence of morphine or DAMGO and Western blotting was performed after 4 h of
treatment. As is evident from Figure 26B, iNOS protein was induced by stimulation with LPS (1
µg·mL-1). This induction was increased by co-treatment with either 100 nM morphine or DAMGO.
We found that the inhibition of PKCε expression by siRNA blocks morphine- and DAMGO
increases in iNOS protein expression in LPS-treated microglia (Figure 26B). These results clearly
show the connection between PKCε, morphine and DAMGO, ERKs and Akt signaling, iNOS
protein, in activated primary microglial cells.
Effect of LPS and morphine on another proinflammatory enzyme, COX-2, was examined by
Western blot assay. Stimulation of microglial cells with LPS 1 µg·mL -1 led to increased expression
of protein for COX-2 (Figure 26C). However, morphine 100 nM did not modulate the increased
expression of COX-2 protein stimulated by LPS (Figure 26C).
PKCε isoform modulates morphine-induced cytokine and nitrite in activated
microglial cells
We measured cytokine and nitrite levels in microglial cells pretreated with the PKCε inhibitor εV1-
2. Then, we went on to investigate how the inhibition of PKCε interferes with the signalling
pathways modulated by LPS and morphine by maintaining primary microglial cells in LPS-
supplemented (1 µg·mL-1) DMEM in combination with the opioid receptor agonist morphine (100
nM) for 24 h. As shown in Figure 27A, LPS-induced IL-1β, TNFα, IL-6 and nitrite release was
significantly increased in the presence of morphine in primary microglial cells. However, the
stimulatory response of morphine on cytokine and nitrite production was reversed in the presence of
the PKCε inhibitor, εV1-2 (Fig. 27A). We found εV1-2 alone significantly inhibited LPS and LPS
plus morphine-induced increase of IL-1β, IL-6, TNF-α and nitrite release. Likewise, we measured
cytokine and nitrite levels in microglial cells in which PKCε was down-regulated by siRNA. We
found that in microglial cells with PKCε down-regulated, morphine and DAMGO did not
significantly increase IL-1β, TNF-α, IL-6 and nitrite protein levels when compared to LPS, after 24
h of treatment (Fig. 27B).
96
Activation of PKCε by morphine in reactive microglia occurs upstream Akt,
ERK1/2 and iNOS
Microglial cells were pretreated with U0126 and SH-5, inhibitors of ERK1/2 and Akt, respectively,
for 30 min before LPS plus morphine stimulation for 10 min. Subsequently, whole-cell lysates were
prepared and analyzed by Western blot analysis for phospho-PKCε. Figure 28A shows that
morphine 100 nM significantly increased phospho-PKCε in activated microglial cells even in the
presence of U0126 and SH-5. These results confirm that activation of PKCε by morphine in
reactive microglia occurs upstream Akt and ERK1/2.
Furthermore, microglial cells were pretreated with U0126 and SH-5, for 30 min before LPS plus
morphine stimulation for 4 h. Subsequently, whole-cell lysates were prepared for Western blot
analysis of iNOS. The results demonstrate that SH-5 and U0126 significantly blocked the ability of
morphine to increase iNOS production in the presence of LPS (Figure 28A), indicating that
activation of Akt and ERK1/2 occurs upstream iNOS production induced by LPS and morphine in
reactive microglia. Moreover, microglial cells pretreated with SH-5 for 30 min before LPS plus
morphine stimulation for 10 min were analyzed for ERK1/2 phosphorylation levels. We found that
the inhibition of the Akt pathway significantly blocked morphine-induced ERK1/2 phosphorylation
in morphine-treated activated microglia (Figure 28B), indicating that Akt proceeds through ERK1/2
activation to mediate chemokine and nitrite production induced by morphine.
Finally, we have investigated the effect of morphine 100 nM alone on signal transduction pathway
in microglial cells. Figure 29A shows that morphine did not modulate PKCε activation, iNOS and
COX-2 protein expression while slightly increased Akt and ERK1/2 phosphorylation. In addition,
we measured cytokine and nitrite levels in microglial cells treated with morphine 100 nM for 24 h.
We found that IL-1β, IL-6, TNF-α and nitrite release was not significantly modulated in the
presence of morphine in primary microglial cells (Figure 29B).
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Discussion and Conclusions
The studies presented here indicate that PKCε has a critical function in the regulation of a number
of signalling pathways that mediate various aspects of microglia activation in response to morphine
treatment. In particular, our findings point to an important role for PKCε in morphine-evoked
inflammatory pathways leading to chemokine and NO production. By using pharmacological
inhibitors and RNA interference, we have clearly demonstrated that morphine-induced iNOS, IL-
1β, TNF-α, IL-6 and NO production in primary activated microglial cells is mediated by a
signalling pathway involving the sequential activation of PKCε, Akt and MAPK, as illustrated in
Figure 30.
The hallmark for PKC activation is a process called translocation, whereby PKC isoforms, once
phosphorylated, translocate from the cytosol to subcellular membrane regions (Freeley et al., 2011;
Steinberg et al., 2008; Mirandola et al., 2011). Presence of a small fraction of membrane-bound
active PKCε form in the unstimulated control cells suggests some activation of PKCε in resting-
state cells. There is evidence that PKCε isoform is activated by opiates. In particular, PKC
inhibitors can reduce morphine anti-nociceptive tolerance (Smith et al., 2007). Mice that lack PKCε
isozyme (PKCε-/-) show enhanced responses to morphine (Newton et al., 2007) and increased
analgesia and thermal behavioral tolerance to specific cannabinoid agonists (Wallace et al., 2009).
Now, for the first time, our findings identified that the novel PKC isoform ε was activated by
morphine in mouse stimulated microglia.
Our group recently demonstrated that morphine enhances the release of NO and the IL-1β, IL-6,
TNF-α proinflammatory cytokines from activated microglial cells through the µ-opioid receptor and
by acting on Akt–ERK1/2 signaling (Merighi et al., 2012a). The present study further extends
earlier findings that the presence of opioid receptors on glia and the ability of morphine to prime
microglia for enhanced production of proinflammatory cytokines supports a possible direct
interaction of morphine with glial cells (Chao et al., 1994). It has been reported that, while agonists
of the µ-opioid receptor are the most appropriate therapy for moderate to severe pain, important
issues of the development of tolerance and dependence diminish their usefulness in patients
requiring chronic treatment. Much work has been done to elucidate the cellular mechanisms of
opioid-induced analgesia, tolerance and dependence in the hope of finding an analgesic that is
capable of enhancing pain relief without initiating the cellular processes involved in tolerance and
dependence. The first report linking glia to morphine tolerance demonstrated that chronic systemic
morphine increased glia activation in the spinal cord (Song et al., 2001). Other authors have also
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shown that chronic morphine administration activates astroglia and microglia (Raghavendra et al.,
2002). Activated microglial cells in the spinal cord may release proinflammatory cytokines and
other substances thought to facilitate pain transmission. It has been reported that glial inhibitors
influence the development of morphine tolerance. Furthermore, glial cells are also considered to be
crucial sources of NO, cytokines and cyclooxygenase products that influence synaptic transmission
in the CNS. Inhibition of these factors may delay morphine tolerance (Watkins et al., 2003; 2001;
2007). Therefore, pharmacological attenuation of glial activation represents a novel approach for
controlling neuropathic pain and tolerance (Ock et al., 2010). It has been indicated that uncontrolled
activation of microglial cells after nerve injury can lead to altered activities of opioid systems or
opioid-specific signaling (Ock et al., 2010; Watkins et al., 2007). It is already known that microglia
release neuroexcitatory substances in response to morphine, thereby opposing its effects (Watkins et
al., 2001; 2007; Ock et al., 2010). This raises an older hypothesis that suppression of glial activation
and the resulting blockade of proinflammatory cytokine synthesis can improve morphine efficacy
(Song et al., 2001; Watkins et al., 2001). The mechanism underlying the involvement of glial cells
in morphine tolerance is unclear. It is possible that morphine can act directly on glial cells
triggering alterations in their morphology and functions (Raghavendra et al., 2002; 2004).
Additionally, glial cells are also considered to be crucial sources of NO, cytokines and
cyclooxygenase products that influence synaptic transmission in the central nervous system (CNS).
Inhibition of these factors may delay morphine tolerance (Powell et al., 1999).
Many current studies aim to find substances inhibiting the biosynthesis of proinflammatory
cytokines. It has been found that propentofylline, minocycline and ibudilast inhibit cytokines and
lower astroglia and microglia activation, thereby suppressing the development of neuropathic pain
(Romero-Sandoval et al., 2008). The beneficial effects of minocycline are associated with a
reduction of inducible NO synthase and cyclooxygenase-2 expression and a decrease in cytokine
and prostaglandin release in microglia (Yrjanheikki et al., 1999; 1993). Further studies have shown
that minocycline reduced microglial activation by inhibiting p38 MAPK in microglia, and in this
way delayed morphine tolerance. It was also suggested that ibudilast may counteract opioid
tolerance by blocking the activation of glial cells in the spinal cord in rodents (Romero-Sandoval et
al., 2008). PKCε is critically involved at an early stage of LPS-mediated signalling in activated
macrophages (Castrillo et al., 2001). Several studies have also implicated MAP kinase activation as
a critical event in LPS-mediated signalling (Hambleton et al., 1996; Geppert et al., 1994; Han et al.,
1994; Reimann et al., 1994; Weinstein et al., 1992). It has been demonstrated that the extent of
ERK1/2 MAP kinase activation is significantly decreased after LPS-stimulation of PKCε -/-
macrophages. Furthermore, our results for the first time suggest that PKCε is critical to the
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reactivity state of microglia, promoting the morphine-induced release of NO and cytokines from
microglial cells. In particular, we found that in activated microglial cells, morphine increased Akt
and ERK kinase phosphorylation through PKCε activation. Activation of Akt pathway is found
closely linked to PKCε activation in our cellular system, although an earlier report has indicated
that Akt pathway may be independent on PKC isoforms (Sun et al., 2009). Distinct stimuli applied
to different cells (microglia vs. macrophages) may account for the differential interaction of the
intracellular pathways.
In summary, in the present study, we identified for the first time the involvement of PKCε isoform
and Akt pathway upstream of ERK1/2 to mediate morphine-induced proinflammatory phenotype in
mouse microglial cells. The establishment of PKCε role in morphine-TLR signalling may provide a
means to treat opioid development of tolerance and dependence. However, because the increase of
the inflammatory cytokines cannot explain the pain tolerance directly, it will be important to
measure the pain mediators, such as substance P, in animal study. Certainly, the in vivo
observations that PKC inhibitors can reduce morphine antinociceptive tolerance (Smith et al., 2007)
provide evidence that selective inhibition of those PKCs involved might provide useful adjuncts to
chronic therapy with opioid drugs. Inhibition of a kinase required for so many important biological
functions may be expected to result in substantial side effects. However, several inhibitors of PKC
have proven to be well tolerated in clinical trials (Budde et al., 2010; Geraldes et al., 2010; Roffey
et al., 2009). We may hope for a similar advance with regard to PKCε selective inhibition.
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Figure Legends
Figure 21: Cellular localization of PKCε by imunofluorescence. Microglial cells were treated with
morphine 100 nM (MOR), LPS 1 µg·mL-1 alone (LPS) or LPS + morphine (LPS + MOR) for 10
min. Control panels (CTR) were drug-vehicle-treated cells. PKCε was revealed by
immunofluorescence with anti-PKCε antibody and detected by goat fluorescein isothiocyanate anti-
rabbit IgG. The fluorescent dye DAPI (blue panel) was used to stain the nuclei. Original
magnification 40x.
Figure 22: Expression and morphine-induced phosphorylation and membrane translocation of
PKCε isoform in LPS-activated primary microglia. Microglial cells were treated with either LPS (1
µg·mL-1) alone or LPS + morphine (100 nM) for 0–60 min. (A) Phospho- and total PKCε
expression in whole-cell lysates. (B) Densitometry of phospho-PKCε expression relative to total
PKCε. (C) PKCε expression in membrane (m) and cytosolic (c) fractions of cells. (D) Densitometry
of membrane vs. cytosolic PKCε. (E) Phospho- and total PKCε expression in membrane fractions
(m) of cells. (F) Densitometry of membrane vs. total PKCε. Plots are mean ± S.E. values of four
separate experiments (one of which is shown) performed in triplicate (n = 4). *P < 0.01 vs. control
conditions (absence of drugs, 0); #P < 0.01 vs. LPS conditions; analysis was by ANOVA followed
by Dunnett’s test.
Figure 23: Effect of opioid receptor ligands on LPS-induced phosphorylation of PKCε isoform in
primary microglia. Microglial cells were treated with either LPS alone, LPS + morphine 100 nM
(MOR), LPS + DAMGO 100 nM, LPS + DPDPE 100 nM, LPS + U69593 100 nM, LPS +
Naloxone 100 nM (NALOX), or LPS + CTAP 100 nM for 10 min. The antagonists were added 30
min before morphine. (A) Phospho- and total PKCε expression. (B) Densitometry of phospho-
PKCε expression relative to total PKCε. Plots are mean ± S.E. values of four separate experiments
(one of which is shown) performed in triplicate (n = 4). *P < 0.01 vs. control conditions (absence of
drugs, CTR); #P < 0.01 vs. LPS conditions (0); §P < 0.01 vs. LPS + MOR; †P < 0.01 vs. LPS +
DAMGO; analysis was by ANOVA followed by Dunnett’s test.
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Figure 24: µ-opioid receptor expression silencing. (A) Primary microglial cells were treated with
either scramble (-) (siRNAcontrol) or with siRNAµ and cultured for 24, 48 and 72 h. Tubulin shows
equal loading of protein. Densitometric quantification of µ-opioid receptor by Western blot is
shown. Plots are mean ± S.E. values of four separate experiments performed in triplicate (n = 4); *P
< 0.01 compared with the control (scramble transfected cells); analysis was by ANOVA followed
by Dunnett’s test. (B) Primary microglial cells were treated with either siRNActr or siRNAµ for 48 h
and cultured with LPS 1 µg·mL-1 alone or plus morphine 100 nM (MOR) for 10 min. Densitometry
of phospho-PKCε expression relative to total PKCε and densitometry of membrane vs. cytosolic
PKCε is shown. Plots are mean ± S.E. values of four separate experiments (one of which is shown)
performed in triplicate (n = 4). *P < 0.01 vs. control conditions (absence of drugs, CTR); #P < 0.01
vs. LPS conditions; analysis was by ANOVA followed by Dunnett’s test.
Figure 25: PKCε is involved in mediating morphine-induced Akt and ERK1/2 activation in
primary microglial cells. Microglial cells were pretreated with εV1-2 (1 mM) for 2 h before LPS
and morphine stimulation for 10 min. Densitometry of membrane vs. cytosolic PKCε is shown. The
ratio of phospho-protein to total protein is used. Plots are mean ± S.E. values of four separate
experiments (one of which is shown) performed in triplicate (n = 4) and normalized to the result
obtained in untreated cell cultures (CTR) set to 100%. *P < 0.01 vs. control conditions (absence of
drugs, CTR); #P < 0.01 vs. LPS conditions; §P < 0.01 vs. LPS + MOR; analysis was by ANOVA
followed by Dunnett’s test.
Figure 26: PKCε expression silencing. (A) Primary microglial cells were treated with either
scramble (-) (siRNAcontrol), or with siRNAPKCε and cultured for 24 and 48 h. Tubulin shows equal
loading of protein. Densitometric quantification of PKCε by Western blot is shown. Plots are mean
± S.E. values (n = 3); *P < 0.01 compared with the control (scramble transfected cells); analysis
was by ANOVA followed by Dunnett’s test. (B) Primary microglial cells were treated with either
siRNActr or siRNAPKCε for 24 h and cultured with LPS 1 µg·mL-1 alone or plus morphine 100 nM
(MOR) or DAMGO 100 nM for 10 min (Akt and ERKs) or 4 h (iNOS). The ratio of phospho-
protein to total protein is used. The mean values of 3 independent experiments (one of which is
shown) were normalized to the result obtained in cells in the absence of LPS. The unstimulated
control was set to 100%. *P < 0.05 with respect to unstimulated control (CTR); #P < 0.05 with
respect to cells treated with LPS; analysis was by ANOVA followed by Dunnett’s test. (C) COX-2
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expression in primary microglial cells treated for 4 h either with LPS 1 µg·mL -1 alone or in
combination with morphine 100 nM. Densitometric analysis is reported. The mean values of 3
independent experiments (one of which is shown) were normalized to the result obtained in cells in
the absence of LPS. *P < 0.05 with respect to unstimulated control (CTR); analysis was by
ANOVA followed by Dunnett’s test.
Figure 27: (A) Effect of εV1-2 on morphine-induced production of proinflammatory cytokine and
nitrite in activated primary microglial cells. Microglial cells were treated with either LPS alone,
LPS + morphine 100 nM (MOR), alone or in the presence of εV1-2. Microglial cells were
pretreated with εV1-2 (1 μM) for 2 h before LPS and morphine stimulation for 24 h. Plots are mean
± S.E. values of four separate experiments performed in triplicate (n = 4). *P < 0.01 vs. control
conditions (absence of drugs, CTR); #P < 0.01 vs. LPS conditions (0); §P < 0.01 vs. LPS + MOR;
analysis was by ANOVA followed by Dunnett’s test. (B) Primary microglial cells were treated with
either siRNActr or with siRNAPKCε for 24 h and cultured with LPS 1 µg·mL-1 alone or plus morphine
100 nM (MOR) or DAMGO 100 nM for 24 h. The unstimulated control (CTR) was set to 100%.
Plots are mean ± S.E. values (n = 3); *P < 0.05 vs. CTR; #P < 0.05 vs. LPS; analysis was by
ANOVA followed by Dunnett’s test.
Figure 28: Primary microglial cells were treated with either LPS 1 µg·mL -1 alone or plus SH-5 1
μM, U0126 1 μM, morphine 100 nM (MOR) alone or in combination for 10 min (p-PKC in panel A
and pERK1/2 in panel B) or 4 h (iNOS). Densitometry of phospho-PKCε expression relative to total
PKCε is shown. Plots are mean ± S.E. values of four separate experiments (one of which is shown)
performed in triplicate (n = 4). *P < 0.01 vs. control conditions (absence of drugs, CTR); #P < 0.01
vs. LPS conditions; §P < 0.01 vs. LPS + MOR; analysis was by ANOVA followed by Dunnett’s
test.
Figure 29: Primary microglial cells were treated with morphine 100 nM (MOR) for (A) 10 min (p-
PKCε, pAkt, pERK1/2), 4 h (COX-2, iNOS) or (B) 24 h (IL-1β, IL-6, TNF-α, nitrite).
Densitometric analysis of phosphorylated isoform is reported. Plots are mean ± S.E. values of four
separate experiments (one of which is shown) performed in triplicate (n = 4). *P < 0.01 vs. control
conditions (absence of morphine, CTR); analysis was by t-test.
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Figure 30: Schematic summary of morphine-initiated signal transduction cascade in murine
microglia. Morphine binding to µ-opioid receptor (µR) activates PKCε, Akt and ERK kinases,
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